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ABSTRACT 
The syntheses and characterization of symmetric and asymmetric Pcs 
functionalized at the peripheral position are reported. The Pcs contain either 
zinc or indium as central metals and have carboxyphenoxy, phenoxy 
propanoic acid, benzothiazole phenoxy, thiophine ethoxy or di-O-
isopropylidene-α-D-glucopyranose as ring substituents. The Pcs were linked 
to NPs via an amide bond or through self-assembly.  
The photophysics and photochemistry of the Pcs were assessed when alone 
and with conjugates. All the studied Pcs showed good photophysicochemical 
behaviour with relatively high triplet and singlet oxygen quantum yields 
corresponding to their low fluorescence quantum yield. The Pcs with indium 
in their central cavity exhibited higher triplet and singlet oxygen quantum 
yields in comparison to their zinc counterparts due to the heavy–atom effect 
obtained from the former. Asymmetrical Pcs displayed higher triplet and 
singlet oxygen quantum yields than their symmetrical counterparts.  
The triplet quantum yield, generally increased on linkage to nanoparticles 
(NPs) due to the heavy–atom effect of gold and silver in NPs. The conjugates 
to gold nanospheres yielded higher triplet and singlet quantum yields than 
their gold nanotriangles counterparts due to the higher loading by the former 
probably encouraged by their relatively small particle size.  
 
The in vitro dark cytotoxicity and photodynamic therapy of selected Pc 
complexes and conjugates against MCF-7 cells was tested. All studied Pc 
complexes and conjugates showed minimum dark toxicity making them 
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applicable for PDT. All complexes displayed poor phototoxicity with > 50% 
cell viability at concentrations ≤ 160 µg/mL, however the conjugates showed 
< 50% cell viability at concentrations ≤ 160 µg/mL probably due to the 
enhanced singlet oxygen quantum yield.  
 
The findings from this work show the importance of linking photosensitises 
such as phthalocyanines to metal nanoparticles for the enhancement of 
singlet oxygen quantum yield and ultimately the photodynamic effect. 
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CHAPTER 1 
 
1. Introduction 
 
Preamble 
The thesis describes the synthesis of symmetrical and asymmetrical 
phthalocyanines (Pcs) containing zinc and indium as central metals. The Pcs 
are linked to Au containing nanoparticles via an amide or Au-S or Au-N bonds. 
The photophysical and photochemical properties of the Pcs and their 
conjugates are studied together with the photodynamic therapy behaviour 
against epithelial breast cancer cell lines (MCF 7). 
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1.1. Phthalocyanines  
Phthalocyanines (Pcs) are planar aromatic macrocycles consisting of an 18 π–
electron conjugated ring with four isoindole units connected via nitrogen 
atoms [1,2]. The Pc macrocycle can be substituted with different functional 
groups on the non–peripheral (α) and peripheral (β) positions (indicated in 
Scheme 1.1, to be discussed later) to influence their physicochemical 
properties which are crucial for their applications. At the same time the 
central cavity of Pcs can coordinate different metals to form 
metallophthalocyanines (MPcs) and these metals are known to influence their 
photophysical behaviour.  
Pc derivatives have attracted attention as second generation photosensitisers 
(PS) for diverse applications such photodynamic therapy (PDT) [3–5], 
photodynamic antimicrobial chemotherapy (PACT) [6–8], photodegradation of 
pollutants [9] and nonlinear optics [10] to mention but a few. Their 
applicability could be attributed to their ease of structural modification, 
absorption in the near infra–red region, and good optical, chemical and 
thermal properties [11–15].  
 
1.1.1. Electronic absorption Spectra 
The ground state electronic absorption spectra of MPcs are often influenced 
by factors such as nature of the central metal, ring substituents, the solvent 
used, point of substitution and ring expansion [16–19]. MPcs are 
characterised by two distinct absorption bands as shown in Figure 1.1.  
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Figure 1.1: Ground state electronic absorption spectrum (insert: molecular 
orbital representation of electronic transition) for MPcs. 
 
The Q-band is the most intense peak found in the visible and near infra-red 
region depending on the structural properties of the MPcs, while the B-band, 
found between 300–400 nm consist of two less intense, overlapping peaks due 
to B1 and B2 hence it is broad [20].  
Using Gouterman’s four orbital model [21], the Q-band is assigned to the 
doubly degenerate π-π* transition between the ground state a1u of the highest 
occupied molecular orbital (HOMO) to the degenerate eg of the lowest 
unoccupied molecular orbital (LUMO), while the B-bands (B1 and B2) 
correspond to the π-π* transitions from a2u and b2u of the HOMO to the eg of 
the LUMO, Figure 1.1 (insert) [20–23]. 
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1.1.2. Synthesis of symmetrical and asymmetrical Pcs. 
The synthesis of phthalocyanines can be achieved using different precursors 
such as: phthalamide, phthalic acid, phthalic anhydride, o-cyanobenzamide, 
o-dibromobenzene, diiminosoindoile and phthalonitrile.  However, the method 
employing phthalonitrile precursors is much more popular due to ease of 
purification and high yields of Pcs [24].  
For the synthesis of α and β-substituted Pcs, 3-nitrophthalonitrile and 4-
nitrophthalonitrile, respectively, are used as precursors. The nitro groups of 
these phthalonitriles are modified to afford the desired substituted 
phthalonitriles for the synthesis of Pcs. Symmetrically tetra–substituted Pcs 
are synthesized by cyclo–condensation of mono–substituted phthalonitriles as 
precursors [25–27], Scheme 1.1.  
Mono–substituted phthalonitriles always result in a mixture of four possible 
isomers of tetrasubstituted phthalocyanines with D2h, C4h, C2V, and Cs 
symmetry as shown in Figure 1.2 (using β substituted Pcs as examples). 
Similar isomers are obtained for the α substituted Pcs. Attempts have been 
made to isolate these isomers and a few have been isolated using column 
chromatography [28,29], however in most cases specially designed high-
performance liquid chromatography (HPLC) columns are required and the 
yield is low. Isometric mixtures have been shown to be suitable for many 
applications including PDT [30].   
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Scheme 1.1: Synthetic route for tetra-substituted MPcs (R represents the 
substituent) 
 
The uniformity of substituents in symmetrical Pcs sometimes limits their 
application where specific binding with other ligands is desired. Hence efforts 
are made towards the design and synthesis of asymmetric Pcs with a unique 
substituent located at a specific position [31]. Asymmetry has been shown to 
be advantageous since it introduces distortions on the phthalocyanine 
macrocyle which affects the electronic states of the conjugated macrocycle 
[30]. This results in improved photophysical properties of the Pcs [32,33] 
which consequently is good for different applications including photodynamic 
therapy. Hence asymmetrical Pcs are employed in this work together with 
symmetrical ones.  
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Figure 1.2: Constitutional isomers of tetrasubstituted phthalocyanines. (For 
each isomer symmetrically nonequivalent nitrogen atoms are shown in 
different colors and R represents the substituent). 
 
Statistical condensation of two differently substituted phthalonitriles is 
generally utilised for the synthesis of A3B-type asymmetrical Pcs, which are 
characterised by three identical (A) isoindole subunits and one different (B) 
subunit, Scheme 1.2. The phthalonitrile precursors are combined in mole 
ratios of 3:1 up to 9:1 (A:B) depending on the reactivity of the substituents 
[31,34–36]. 
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Scheme 1.2: Statistical mixed condensation products of phthalonitriles A 
and B. 
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A mixture of six products could be obtained as shown in Scheme 1.2 and 
these are separated chromatographically to isolate the desired Pc (A3B or AB3).  
 
1.1.3. MPcs synthesised and studied in this work 
In this work both symmetrical and asymmetrical peripherally substituted 
MPcs are synthesised containing either zinc or indium as central metals and 
with carboxyphenoxy, phenoxy propanoic acid, benzothiazole phenoxy, 
thiophine ethoxy and di-O-isopropylidene-α-D-glucopyranose as ring 
substituents, Table 1.1. Complexes 1, 3a, 3b and 4a have been reported 
before [37–40]. However, their photophysical and photochemical behaviour in 
the presence of gold or gold silver alloy or gold speckled silica nanoparticles 
are explored for the first time. Complexes 2, 4b, 5, 6, 7 and 8 are reported 
here for the first time.  
 
1.1.3.1. Choice of central metal. 
Metal centres influence photophysical and photochemical properties of Pcs. 
In and Zn were chosen because they are diamagnetic hence they have a closed 
shell structure which results in enhanced photophysical properties. 
Additionally, as heavy atoms; they promote intersystem crossing to populate 
the triplet state through the spin orbit coupling (SOC). SOC (also termed 
heavy atom effect, HAE) is most prevalent in atoms whose nuclei are large and 
enhances the kinetics of both radiative and non-radiative transitions between 
states with different spin [41,42].  
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Table 1.1: MPcs and conjugates synthesised in this work 
MPc Conjugate (bond 
formed) 
 
Symmetric MPcs 
N
N
NNN
N
N N
In
O
O
HO
O
O
OO
HO
O
HO
OH
O
OH
 
Indium(III) tetra–(3–carboxyphenoxy) 
phthalocyanine (1). [37] 
1-Ag1Au3NSs-GSH 
1-Ag3Au1NSs-GSH 
1-Ag3Au1SiNSs- APTES  
  
(amide bond) 
N
N
N
N
N
N
N
N
O
OO
O
Zn
O
HO
O
HO
O
O
OH
OH  
Zinc(II) tetra–[3-(4-phenoxy)propanoic acid] 
phthalocyanine (2). [New]  
2-AuNTs-GSH 
2-AuNSs-GSH 
2-AgNSs -GSH 
2-Ag3Au1NSs-GSH 
 
(amide bond) 
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N
N
N
N
N
N
N
N
O O
O
M
N
S
N
S
N
S
O
N
S
 
Zinc(II) [tetra-(benzothiazol-2-yl)phenoxy] 
phthalocyanine (3a). M= Zn [38] 
Indium(III) chloride [tetra-(benzothiazol-2-
yl)phenoxy] phthalocyanine (3b). M= In(Cl) [39]  
3a-AuNTs-CTAC 
3a-AuNSs-CTAB 
3a-GSS 
 
3b-AuNTs-CTAC 
3b-AuNSs-CTAB 
3b-GSS (PDT studies) 
 
(Au-S/Au-N bond) 
    
Zinc(II) tetra-(thiophine ethoxy) phthalocyanine 
(4a). M= Zn [40] 
Indium(III) chloride tetra–(thiophine ethoxy) 
phthalocyanine (4b). M= In(Cl) [New] 
4a-AuNTs-CTAC 
4a-AuNSs-CTAB 
4a-GSS 
 
4b-AuNTs-CTAC 
4b-AuNSs-CTAB 
4b-GSS 
 
(Au-S bond) 
 
Asymmetric MPcs 
N
N
N
N
N
N
N
N
O
Zn
O OH  
Zinc(II) mono–[3-(4-phenoxy)propanoic acid] 
phthalocyanine (5). [New] 
5-AuNTs-GSH 
5-AuNSs-GSH 
5-AgNSs -GSH 
5-Ag3Au1NSs-GSH 
 
(amide bond) 
N
N
N
N
N
N
N
O
OO
O
S
S
S
S
M
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N
N
N
N
N
N
N
N
O
OO
O
Zn
O OHN
S
N
S N
S
 
Zinc(II) [tris-(4-(benzothiazol-2-yl)phenoxy)- 3-(4-
phenoxy)propanoic acid] phthalocyanine (6). 
 [New] 
6-AuNTs-CTAC 
6-AuNSs-CTAB 
6-AuCT (PDT studies) 
 
 (Au-S/Au-N bond) 
 
6-CT (S-N bond) 
6-AuNTs-GSH 
6-AuNSs-GSH 
 
(amide bond) 
N
N
N
N
N
N
N
N
O
OO
O
Zn
O OH
N
S
O
HO
O
HO  
Zinc(II) [tris-(3-(4-phenoxy)propanoic acid)-4-
(bezothiazol-2-yl) phenoxy] phthalocyanine (7). 
[New] 
 
7-AuNTs-GSH 
7-AuNSs-GSH 
(amide bond: un 
published work) 
 
 
 
 
7-AuNTs-CTAC 
(Au-S/Au-N bond) 
N
N
N
N
N
N
N
N
O
OO
O
Zn
OO
O
O O
O
O
O
O
O
O O
O
O
O
N
S
 
Zinc(II) [(tris- (2,2,7,7-tetramethyltetrahydro-3aH-
bis([1,3] dioxolo)[4,5-b:4',5'-d]pyran-5-
yl)methoxy)-2-(4-benzothiazol-2-yl)phenoxy] 
phthalocyanine (8). [New] 
8-AuNRs-CTAB 
8-AuNSs-CTAB 
 
(Au-S/Au-N bond) 
 
(PDT studies) 
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The probability of intersystem crossing to triplet state thus increases with an 
increase in the atomic number of elements and this reduces fluorescence 
[43,44]. This makes heavy metals such as In and Zn a good choice as central 
metals in MPcs for PDT.  
 
1.1.3.2. Choice of substituent. 
Substituents greatly influence the behaviour of Pcs especially the 
photophysical and photochemical properties together with their applications 
[45,46].  
i) The carboxyphenoxy (in complex 1) was chosen as a ring substituent 
due to the promising PDT activity displayed by zinc tetra 
phthalocyanine with carboxyphenoxy groups [47].  
ii) The phenoxy propanoic acid substituent (in complexes 2, 5, 6 and 7) 
was chosen based on the fact that porphyrins containing propanoic acid 
(such as the Uroporphyrins) have been successfully employed for PDT 
[4] and in addition, phenyl rings are reported to contribute to effective 
population of the triplet state [48]. MPcs with a phenoxy propanoic acid 
substituent (both symmetric and asymmetric) are synthesised here for 
the first time.  
iii) The benzothiazole phenoxy substituent (in complexes 3a, 3b, 6, 7 and 
8) was chosen since benzothiazole derivatives have been found to have 
antitumor activities [49–51] which could be advantageous for PDT 
applications. Additional phenyl rings could also be an advantage as 
explained before. 
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iv) The thiophine ethoxy substituent (in complexes 4a and 4b) was used 
because of the reported anticancer potential of thiophene derivatives 
[52,53].  
v) A saccharide (1,2:3,4-di-O-isopropylidene-α-D-glucopyranose) as a 
substituent (in complex 8) was chosen for improved cell-uptake since 
cancer cells are known for increased glucose uptake and glycolysis to 
provide sufficient metabolic energy to sustain their proliferation. The 
glucose transporter proteins are over-expressed in a variety of human 
carcinomas [54] and glycoconjugation of MPc could enhance their 
cellular uptake and eventually the PDT efficacy. 
 
1.1.3.3. Choice of the nanoparticle capping agent  
In this work, glutathione (GSH) functionalised or cetyltrimethylammonium 
bromide/chloride (CTAB/CTAC) stabilised gold nanoparticles (spheres, 
AuNSs-GSH/AuNSs-CTAB; rods, AuNRs-CTAB and triangles, AuNTs-
GSH/AuNTs-CTAC), silver nanospheres (AgNSs-GSH), gold-silver alloy 
nanospheres (Ag3Au1NSs-GSH and Ag1Au3NSs-GSH, numbers are mole ratios 
of Ag : Au in the alloy), gold-silver alloy coated with silica nanospheres and 
functionalised with aminopropyl triethoxylsilane (Ag3Au1SiNSs–APTES), gold 
speckled silica nanoparticles (GSS), chitosan (CT) and a gold chitosan (AuCT), 
composite, Figure 1.3, were synthesised and attached to MPcs for possible 
application in PDT. Table 1.1 shows the synthesised MPcs and their 
conjugates with nanoparticles. 
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Figure 1.3: An illustration of nanoparticles used in this work. 
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The MPcs were linked to these NPs taking advantage of:  
i) the high affinity of gold in the NPs for sulphur or nitrogen in the 
complexes. The complexes with thiophine (complexes 4a and 4b) or 
benzothiazole (complexes 3a, 3b, 6, 7 and 8) groups, were linked to 
AuNPs (either AuNSs-CTAB, AuNRs-CTAB or AuNTs-CTAC), GSS and 
AuCT, via a Au-S/Au-N bond. 
ii) Complexes with carboxylic acid groups, were covalently linked to either 
glutathione functionalized NPs or aminopropyl triethoxylsilane 
functionalized NPs (Ag3Au1SiNSs–APTES; for complex 1). GSH and 
APTES were used as capping bifunctional ligands for the NPs due to the 
availability of an amine moiety in their molecular structure which can 
foster amide bond formation with a –COOH containing phthalocyanine. 
 
1.1.3.4. Comparative Studies. 
The complexes alone and at times with NPs will be compared to study the 
effect of substituents, central metal and symmetry on the photophysical and 
photochemical properties. For asymmetric MPcs the effect of the number of 
substituents will also be compared. 
i) Symmetrically substituted complexes 2, 3a and 4a (with Zn as the 
central metal), will be compared for the effect of ring substituents on 
the photophysical and photochemical properties. The same applies 
for complexes 1, 3b and 4b (with In as the central metal). 
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ii) Complexes 3a and 3b, 4a and 4b will be compared for the effect of 
the central metal on the photophysical and photochemical properties 
in the absence and in the presence of NPs. The same complexes will 
be compared for the effect of NPs shape and size. Complex 3b and 
its conjugate with GSS will be used as an example for in vitro dark 
cytotoxicity and PDT activity against MCF-7 breast cancer cells. 
iii) The effect of the number of propanoic acid groups on the 
photophysical and photochemical properties will be studied by 
comparing complexes 2 (with four phenoxy propanoic acid groups) 
and 5 (with one phenoxy propanoic acid group) when alone and with 
NPs.  
iv) The effect of the number of benzothiazole phenoxy groups will also 
be compared using complexes 3a (with four benzothiazole phenoxy 
groups), 6 (with three benzothiazole phenoxy groups and one 
phenoxy propanoic acid group) and 7 (with one benzothiazole 
phenoxy group and three phenoxy propanoic acid groups), with and 
without NPs. Complex 6 and its conjugate with AuCT (6-AuCT) will 
be used as an example for in vitro dark cytotoxicity and PDT activity. 
v) Complexes 7 and 8, with one common substituent (benzothiazole 
phenoxy group) will be compared for the effect of phenoxy propanoic 
acid versus di-O-isopropylidene-α-D-glucopyranose groups on the 
photophysical and photochemical properties. Complex 8 and its 
conjugates with AuNPs (AuNRs-CTAB, AuNSs-CTAB) will be used as 
an example for in vitro dark cytotoxicity and PDT activity against 
MCF-7 breast cancer cells. 
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vi) Complex 1, with a carboxyphenoxy group, will be used to compare 
the effect of alloy nanoparticles on the photophysical and 
photochemical properties. This also applies for complexes 2 and 
complex 5. 
 
 
1.2. Photodynamic Therapy (PDT) 
PDT is a clinically approved, minimally invasive cancer treatment which 
requires a photosensitizer (PS) and light of appropriate wavelength in the 
presence of ground state molecular oxygen to elicit selective destruction of the 
tumor cells [4]. The three components (a PS, visible light and molecular 
oxygen) are nontoxic when separate, however when the PS is activated by 
visible light, the excited PS reacts with molecular oxygen leading to the 
production of reactive oxygen species (ROS), capable of inducing stress on 
tumorigenic cells [4,55–57].  
PDT is particularly useful for the treatment of early and localised tumours, 
due to the selective delivery of the PS to cancerous tissue [5,58]. However, 
complete cure of metastatic tumours is more challenging since irradiation of 
the whole body is not possible [5,59]. 
MPcs have proven to be an efficacious PS for PDT of cancer and some of them 
have been approved in countries such as Russia, United States of America 
and United Kingdom, for the treatment of cancer. Figure 1.4 shows the 
phthalocyanines that are in clinical trials [60,61].  
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Figure 1.4: Some MPcs in clinical trials as PS for PDT. 
 
1.2.1. PDT mechanisms when using MPcs as PS. 
During photosensitisation as shown in Scheme 1.3, the MPc (as a PS) is 
irradiated with light of a specific wavelength, usually between 400-800 nm 
[57]. The MPc in the ground state (S0) absorbs light, which provides energy for 
the MPc to reach an electronically excited singlet state (S1). The S1 state has 
an unstable and short half-life (10-9 s) [62], leading to fast deactivation 
through either radiative (such as fluorescence) or non-radiative processes, 
like intersystem crossing (ISC). Ideal MPcs undergo deactivation through ISC 
to a triplet excited state (T1). The longer half-life (10-3 s) of the T1 state [62] 
compared to S1, allows for sufficient time for photosensitisation by the excited 
MPc.  
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Scheme 1.3: Schematic representation of Type 1 and Type II photochemical 
reaction mechanisms. 
 
Photosensitisation occurs in three ways, which are either Type I, Type II or 
Type III. Type I involves the interaction of the MPc in the T1 state and a 
substrate (RH), resulting in electron or hydrogen transfer to form free radicals 
which react with molecular oxygen (3O2), to form an oxidised substrate. 
Type II mechanism involves the transfer of energy from the MPc in the T1 state 
to molecular oxygen, producing a highly reactive oxygen species, singlet 
oxygen (1O2) which induces oxidative stress in the cells [57,58,62,63]. Type II 
is the most common mechanism followed in PDT due to the high oxygen 
concentration in most tumors. 
Type III reaction mechanism (Figure not shown), involves an electron 
transfer that occurs between the MPc in the T1 state (3MPc*) and the substrate 
resulting in an anionic MPc and a cationic substrate. Another electron 
transfer then occurs where the anionic MPc transfers an electron 
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to 3O2 forming the superoxide anion, O2−. This transfer returns the MPc to its 
ground state. The superoxide anion and cationic substrate then interact to 
form the oxygenated product. 
 After photosensitisation, malignant cell death can be from direct 
photodamage, vascular shutdown and the activation of an immune response 
[58,59,64,65] if not all of them at once.  
 
1.2.2. Nanoparticles in PDT. 
In spite of the many successes recorded for the PDT activity of MPcs, there 
remain some limitations associated PS in general, and these include lack of 
selectivity and specificity towards cancer cells in comparison to healthy ones 
[62,66]. To address these limitations, various approaches have been explored. 
These include encapsulation of the PS in colloidal carriers (such as liposomes 
[67,68], polymeric micelles [69,70]) and conjugation of the PS to either 
antibodies [71], synthetic peptides [72], nanoparticles [73,74] or 
carbohydrates [75–80]. This work focusses on the linkage of MPcs to 
nanoparticles (NPs) for drug delivery, hence only nanoparticles will be 
discussed.  
Nanoparticles are defined as materials with size ranging from 1 nm to 100 
nm. They have been shown to effectively enhance the selectivity and specificity 
of PS for tumour cells, through enhanced permeability and retention (EPR) 
effects. EPR effect is a phenomenon by which molecules of certain sizes tend 
to selectively accumulate in solid tumor tissues but not in normal tissue (pore 
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size less than 10 nm) because of the abnormal leaky, disorganised and 
loosely-connected blood vessels (with pore sizes of 100-600 nm) in tumor 
tissues [81–84]. Additionally, the poor lymphatic drainage in tumours allows 
nanoparticles to be retained after internalisation due to the inability of 
tumours to renew and clean the interstitial fluid. 
Nanoparticles as a result are ideal carriers of PS for PDT due to their tunable 
size that can be made to be between 10 nm-100 nm, allowing easy 
permeability through the pores of the leaky vasculature (and not normal 
tissue). These particles have additional advantages due to their unique size 
and shape dependent photophysical and photochemical properties as well as 
the extensive possibilities for size and shape control [81,85–87]. Their large 
surface area to volume ratio combined with ease of surface modifications 
allows for attachment to other molecules, hence they are utilised for various 
biomedical applications. Additionally, a high number of PS molecules can be 
accommodated, which increases the amount of PS loaded and delivered to the 
cancer cells, and results in enhanced production of 1O2 and other ROS 
[85,87].  
Additionally, metal nanoparticles can convert certain wavelengths of light into 
heat, since they contain electrons that are free to move throughout the metal. 
Depending on the size and shape of the nanoparticles, these free electrons 
absorb light energy, making the cloud of free electrons on the surface of the 
metal nanoparticles to resonate hence generating heat. As a result, metal 
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nanoparticles are utilised for photothermal therapy (PTT) of cancer. PTT can 
be combined with PDT [82,87] for synergistic destruction of tumorigenic cells.  
 
1.2.3. Nanoparticles linked to Pcs 
The nanoparticles: AuNSs, AuNRs, AuNTs, AgNSs, gold-silver alloy, GSS, CT 
and a AuCT composite have been used before [88–109] for various applications 
including photothermal therapy (PTT), as shown in Table 1.2.  
Table 1.2: Nanoparticles synthesised in this research work and their 
applications 
Nanoparticle Application of NPs 
AuNPs:    
Spheres, Rods 
Triangles 
 
Bioimaging, Biosensing, photothermal therapy, Catalysis, 
drug delivery, PDT, PACT [88,89,100,103].  
Vapour sensing catalysis, photothermal therapy 
[104,105]. 
AgNPs Wound dressing, water purification, catalysis [106–108]. 
Gold- silver 
alloys (AgxAuy) 
Catalysis, bioanalysis, nonlinear optics, antitumor 
activity [90–92,109]. 
Ag3Au1SiNSs–
APTES 
New 
Gold speckled 
silica NPs (GSS)  
Photothermal therapy, bioimaging [93,94]. 
Chitosan (CT) Antitumour activity, drug delivery [95–97]. 
Gold Chitosan 
(AuCT) 
Catalysis, Sensing, PTT [98,99,101,102]. 
 
Table 1.3 shows the reported Pcs which have been linked to NPs employed in 
this work, together with their applications [72, 108-129].  
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Table 1.3: Examples of various Pcs and their conjugates to the nanoparticles 
for different applications  
Pcs NPs (bond 
formed) 
Application Ref 
MPc-AuNPS 
N
N
N
N
N
N
N
NZn
O
N
H
O
S CH3
O
 
9 
Spheres 
 
(Au-S) 
Dye-sensitized 
solar cells 
(DSSCs) 
[110] 
N
N
N
N
N
N
N
NZn
C6H13
C6H13
C6H13
C6H13
C6H13
C6H13
H3C
(CH2)9
SH
 
10 
Spheres 
 
(Au-S) 
Photochemistry 
PDT 
[72, 
109] 
N
N
N
N
N
N
N
NM
SS
S
N
S
N
N
N
N
N
N
N
H2N
H2N
NH2
NH2
NH2
NH2H2N
H2N
 
11a. M= Zn 
 
11b. M= In 
Spheres  
 
(Au-N)  
Photophysics 
 
Photochemistry 
[112]  
N
N
NN
N
N
N N
O
O
O
HN
Zn
O
SH
 
12 
Spheres  
 
(Au-S) 
Photophysics 
 
Photochemistry 
[113] 
24 
 
 
N
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N
N
N
N
N
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S
N F
F
FOH
O
  R
1
= R2=
S OHR1=R2
 =
13.
14.  
 
Spheres  
 
(Au-S/Au-N) 
Photophysics 
 
Photochemistry 
[113] 
N
N
N
N
N
N
N
NZn
O
R R
O
R
OO
R
R = O
-
R = CH2(CHOH)4CH2N
-
CH3
15.
16.  
 
Positively 
charged 
CTAB 
coated rods 
 
 
(mixture: 
electrostatic 
interactions) 
PDT [114] 
N
N
N
N
N
N
N
NZn
O
O
O
O
S S
S
N+
S
N+
N+N+
H3C
CH3H3C
CH3
N
N
N
N
N NN N
NH2
NH2 H2N
H2N
H2N NH2 H2N
NH2
 
17 
rods  
(Au-S/Au-N) 
Photophysics [115] 
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N
N
N
N
N
N
N
NAl
SS
S S
OH
N+ N+
N+
N+
H3C
H3C
CH3
CH3
CH3
H3C
CH3
H3C
CH3
CH3
H3C
H3C
 
18 
rods 
bipyramids 
 
(Au-S) 
 
PACT  [116]  
N
N
N
N
N
N
N
NM
RR
R R  
 
 
            19a. M= Al(Cl); R= SO3- 
 
           19b. M= Al(OH); R= SO3Na 
 
           19c. M= Zn; R= SO3Na 
 
            20.   M= Zn; R= SCH2CH2COOH 
 
            21.   M= Zn; R= SCH2COOH 
stars 
spheres 
rods 
 
(mixture: 
electrostatic 
interactions) 
Photophysics, 
PDT and PTT 
[117,
118] 
MPc-AgNPS 
   
N
N
N
N
N
N
N
N
R
RR
R
Zn
O
N
H
R =
R =  NH2
22.
23.  
Spherical  
AgNPs 
(Ag-N) 
photocatalysts 
for degrading 
organic 
pollutants. 
[119,
120] 
N
N
N
N
N
N
N
NZn
O
O
OH
O
 
 
24 
Spherical  
AgNPs 
cysteamine 
capped 
(amide) 
PDT [121] 
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MPc-gold- silver alloys 
11a Spherical  
Ag3Au1 and  
Ag1Au3NPs 
 
(Au-S/Au-N) 
 
Non linear 
optics 
[122] 
19b Spherical 
AuAg-NPs 
(mixture: 
electrostatic 
interactions) 
 
PACT [123]  
24 Spherical 
AgAu NPs 
cysteamine 
capped 
(amide) 
 
PDT [121] 
MPc-CT and MPc-AuCT composite 
N
N
N
N
N
N
N
NM
SO3
-O3S
-
O3S SO3
-
 
25. M= Ni 
 
26. M= Cu 
 
27. M= Fe 
 
28. M= Co  
Spherical 
CT (for 25-
28) 
 
 
(mixture) 
 
sensing, 
catalysis,  
photocatalysis 
(degradation of 
pollutants).  
[124
–
126] 
AuCT (for 
CoPc (28) 
only)  
(mixture: 
electrostatic 
interactions) 
 
 
 
 
catalysis [127] 
27 
 
N
N
N
N
N
N
N
NM
RR
R R  
                       29. M= H2, R=H  
 
                       30. M= Zn, R= NH2  
 
                       31. M= Zn, R= H 
 
                       32. M= Zn, R= O(C6H4)CHO 
 
CT-TiO2 
(for H2Pc 
(29) only) 
 
catalysis  
 
[128] 
CT (for 30-
32) 
 
(mixture) 
 
cell cytoxicity, 
antibacterial, 
catalysis, 
 
[120,
129,
130]  
   
N
N
N
N
N
N
N
NZn
O
O
OH
  
 
33  
CT 
(mixture) 
PDT  [131] 
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As shown in Table 1.3, AuNTs and GSS nanoparticles have never been linked 
to Pcs and their linkage to Pcs is reported in this work for the first time. AuNTs 
are good for PDT since they have shown better cellular uptake compared to 
other anisotropic nanoparticles (order of cellular uptake efficiency: triangles 
> rods> stars) [132]. GSS nanoparticles have shown some photothermal 
therapy (PTT) effect [93] which might bring a synergistic effect of PDT and PTT 
when they are linked to MPcs for cancer treatment.  
On the other hand, very few asymmetric Pcs have been linked to NPs 
(especially gold containing NPs) and tested for in vitro dark cytotoxicity and 
PDT activity. In this work the linkage of novel asymmetric MPcs to NPs 
containing gold, together with in vitro dark cytotoxicity and PDT activity is 
reported.  
Also shown in Table 1.3, is that very few gold silver alloy nanoparticles have 
been linked to Pcs. Alloying reduces the toxicity of silver in biomedical 
applications and encapsulating the alloy with non-toxic amorphous silica is 
expected to effectively eliminate the toxic effects of silver. In this work the 
silver rich alloy (Ag3Au1) nanospheres were coated with aminopropyl 
triethoxylsilane (APTES) functionalised silica nanospheres for the first time. 
The NPs (Ag3Au1SiNSs–APTES) were further linked to an MPc (complex 1) via 
an amide bond.  
Mixtures of AuCT with MPcs have been used before (Table 1.3), however the 
linkage of an asymmetric Pc to AuCT via a Au-S interaction is reported in this 
work for the first time. 
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1.3. Choice of nanoparticles used in this work 
The size and shape of NPs can influence the physichochemical properties of a 
material, leading to different applications [133], hence different shapes are 
employed in this work.  
1.3.1. Gold Nanoparticles 
Gold nanoparticles (AuNPs) exhibit unique optical, chemical, and biological 
properties hence they are of clinical interest in several applications including 
drug delivery. The attractive features of gold nanoparticles are their surface 
plasmon resonance, the controlled manner in which they interact with thiol 
and nitrogen groups, biocompatibility and the tunability of properties by 
changing the particle size, shape and surface chemistry [134–136]. These 
attributes are exploited to provide an effective multifunctional platform for 
imaging and diagnosis of diseases and to selectively deliver therapeutic agents 
[88,137,138] as indicated in Table 1.2. The use of gold nanoparticles can also 
increase the stability of the drugs.  
Despite the extensive reports on the advantages of anisotropic particles over 
nanospheres, there is still limited research on the linkage of drugs like 
phthalocyanines to anisotropic gold nanoparticles. As stated above and as 
shown in Table 1.3, Pcs have been linked to gold nanospheres and a few to 
nanorods. There are no reports on linkage to nanotriangles. Hence in this 
work, the conjugates of MPcs to gold nanorods and triangles are compared to 
their nanosphere counterparts. 
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The shape of nanoparticles has been reported to influence the delivery system 
of drugs. Non-spherical (anisotropic) particles exhibit significant advantages 
over their spherical counterparts. Anisotropic particles exhibit desirable 
properties such as enhanced circulation time and efficient tumor penetration. 
The anisotropic nanoparticles stick to the surface of a tumor longer than a 
spherical shaped nanoparticles, providing more efficient transfer of 
therapeutic drugs to the tumor [139,140].  
In this work gold nanotriangles (AuNTs-CTAC and AuNTs-GSH represented in 
Figure 1.3) are linked to MPcs (complexes 3a, 3b, 4a, 4b, 6 and 7 for AuNTs-
CTAC; complexes 2, 5, 6 and 7 for AuNTs-GSH) for the first time.  
 
1.3.2. Silver (AgNSs) and silver-gold alloy nanospheres (Ag3Au1NSs 
and Ag1Au3NSs) 
Silver nanoparticles (AgNPs) just as AuNPs exhibit unique optical, chemical, 
and biological properties making them attractive for biomedical applications. 
However, the silver surface easily oxidizes under ambient conditions reducing 
its plasmonic performance and also making it toxic due to the rapid 
dissolution of the surface oxide layer releasing Ag+ ions [141,142]. This 
prohibits the use of nanosilver in biomedical applications where inert 
materials are sought. 
To minimize the toxicity of silver nanoparticles and reduce the use of 
expensive gold, alloy (bimetallic) nanoparticles have been used alternatively 
31 
 
in biomedical applications [143]. These bimetallic nanoparticles exhibit 
unique catalytic, electronic and optical properties distinct from those of the 
corresponding metallic particles. Alloyed silver–gold nanoparticles, resist 
surface oxidation making them applicable for drug delivery. The toxicity of 
silver can also be reduced by encapsulating it with non-toxic amorphous silica 
to reduce Ag+ ion release and direct nanosilver contact with biological systems 
[144,145]. It is for this reason that the Ag3Au1NSs were encapsulated with 
silica nanospheres (SiNSs). Hence, in this work the effects of AgNSs-GSH, 
AuNSs-GSH, Ag3Au1NSs-GSH, Ag1Au3NSs-GSH and Ag3Au1SiNSs–APTES, 
represented in Figure 1.3, on the photophysicochemical behaviour of MPcs 
are evaluated. The synthesis of Ag3Au1SiNSs–APTES (the subscripts are the 
mole ratios) and their linkage to an MPc (complex 1) is reported for the first 
time. 
 
1.3.3. Gold speckled silica nanoparticles  
As stated above, gold and silica nanoparticles have attracted attention in 
biomedical applications, due to their excellent biocompatibility, and ease of 
surface modification [146–150]. A hybrid of gold and silica nanoparticles, 
represented in Figure 1.3, termed gold speckled silica (GSS) nanoparticles 
consist of a silica core with discontinuous, irregular specks of nanogold on the 
surface and within the pores of the silica matrix.  
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The dielectric–metal interfaces enables the GSS nanoparticles to absorb a broad 
spectrum of light from the visible to near infra-red regions—facilitating their use 
as photothermal therapy agents. These nanoparticles have demonstrated high 
thermal stability and good PTT in vitro using the lung A549 cancer cell lines [93]. 
The localized rise in the temperature of GSS particles leads to the rapid injury 
and death of the cancer cells [151]. Gold nanoparticles on their own are 
photothermally unstable, gradually losing their photothermal converting 
capacity upon repetitive near infrared irradiation [152,153] making the use of 
GSS advantageous. Since both silica and gold are generally regarded as safe 
biomaterials, with gold–silica nanoshells currently undergoing early phase 
clinical trials [93], the combination of silica and gold in GSS nanoprticles hold 
potential for use in both photothermal therapy and drug delivery for 
photodynamic therapy. Hence in this work GSS nanoparticles are linked to MPcs 
(complexes 3a, 3b, 4a and 4b) for the first time to assess their singlet oxygen 
generation capacity and the PDT activity.  
 
1.3.4. Gold chitosan composite. 
Chitosan (CT), a polysaccharide composed of glucosamine and N-
acetylglucosamine, is biocompatible, biodegradable, bioactive, mucoadhesive 
and has several functional groups making it an excellent candidate for diverse 
biomedical and pharmaceutical applications including drug delivery [154–
156], Table 1.2. The amino groups in chitosan easily interact with metal 
nanoparticles. Due to the affinity of gold for nitrogen, gold nanoparticles can 
be easily supported on chitosan using Au-N interactions, Figure 1.3. The CT 
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amine group is protonated and positively charged in slightly acidic solution, 
making it to easily form complexes with oppositely charged materials and it 
solubilises in aqueous environments. 
Chitosan has demonstrated antitumor activity suggested to be due to its 
ability to induce cytokines production through increased T-cell proliferation 
and strong pro-apoptotic effects against tumor cells. In drug delivery chitosan 
and its derivatives improve drug absorption, stabilize drug constituents for 
drug targeting in addition to drug release enhancement [157]. As shown in 
Table 1.3, chitosan and the gold chitosan composite have been mixed with 
Pcs before [120,124–131], however this work reports their linkage to an 
asymmetric MPc (complex 6) via Au-S/Au-N self-assembly for PDT. The in 
vitro dark cytotoxicity and PDT studies of the MPc (complex 6) alone and when 
linked to AuCT are reported here for the first time. 
 
 
1.4. Photophysicochemical Parameters 
The photophysical properties of phthalocyanines determine their applicability 
as photosensitizers in different areas including PDT. These properties are 
measured by the changes in the electronic states when light is absorbed. The 
Jablonski diagram (Figure 1.5), illustrates the processes that occur on 
absorption of light by a photosensitizer. Briefly, the photosensitiser molecule, 
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in this case the phthalocyanine, in its singlet ground state (S0) absorbs light 
energy and get excited to the singlet excited state (S1).  
 
 
Figure 1.5: A modified Jablonski diagram showing the transitions between 
ground state (S0) and electronic excited states (S1 and T1). S1= singlet excited 
state, T1= first triplet state, A= absorption, F= fluorescence, IC = internal 
conversion, VR= vibrational relaxation, ISC= intersystem crossing, P= 
phosphorescence, ET = energy transfer, S-S absorption=excited state singlet 
to singlet absorption and T-T absorption= excited state triplet to triplet 
absorption. 
 
 
In the S1 excited state it can either revert to the singlet ground state by 
releasing a photon of light via vibrational relaxation resulting in fluorescence 
(F), or it can undergo intersystem crossing (ISC) to the triplet state, T1 [158–
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160]. The photosensitiser transfers energy from the excited triplet (T1) to 
ground state molecular oxygen (3O2) generating a reactive singlet oxygen (1O2) 
species that destroys cancers cells [4].  
The photophysicochemical parameters of phthalocyanines are fluorescence 
quantum yield (ΦF) and lifetime (τF), triplet quantum yield (ΦT) and lifetime (τT) 
and the singlet oxygen quantum yield (ΦΔ). These are important in the 
determination of the suitability of the molecules as photosensitisers 
[161,162]. 
 
1.4.1. Fluorescence quantum yields (ΦF)  
The fluorescence quantum yield (ΦF) is defined by the ratio of the number of 
photons emitted to the number of photons absorbed. The fluorescence 
quantum yield values are determined using a comparative method [163,164] 
where the emission spectrum of a sample is compared with that of a standard 
on excitation at the same wavelength. The ΦF are calculated according to 
Equation 1.1.    
ΦF = ΦF(Std)
𝐹𝐹.𝐴𝐴𝑆𝑆𝑆𝑆𝑆𝑆.𝑛𝑛2
𝐹𝐹𝑆𝑆𝑆𝑆𝑆𝑆.𝐴𝐴.𝑛𝑛𝑆𝑆𝑆𝑆𝑆𝑆2    (1.1) 
where F and FStd are the areas under the fluorescence curves of the sample 
and the standard, respectively. A and AStd are the absorbances of the sample 
and standard at the excitation wavelength, and n and nStd are the refractive 
indices of the solvents used for the sample and standard, respectively. ΦFstd 
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is the fluorescence quantum yield of the standard and unsubstitued zinc 
phthalocyanine (ZnPc) in DMSO (ΦF = 0.2 [46]) was used as a standard. 
Factors such as the nature of solvent used, pH, aggregation, temperature, 
nature of central metal, concentration, nature of substituents and point of 
substitution have been reported to influence the ΦF of MPcs.   
The fluorescence life-time (τF),) is the average time a molecule spends in its 
excited singlet state before reverting to the ground state through fluorescence. 
The time-correlated single-photon counting (TCSPC) technique [165,166] was 
used to determine the τF values of all the MPcs and their conjugates studied 
in this work.  
 
1.4.2. Triplet quantum yields  
The triplet quantum yield (ΦT) measures the fraction of absorbing MPcs that 
undergo rapid intersystem crossing (ISC) from the lowest excited singlet state 
to populate the lowest excited triplet state (T1). The triplet lifetime is the 
amount of time it takes the triplet state to be completely depopulated and is 
indicative of the available time for the triplet state MPcs to transfer energy to 
ground state molecular oxygen or other substrates.  
A comparative method [167,168] using a standard was used for triplet 
quantum yields determination based on triplet decay, using equation 1.2. 
ΦT = ΦTStd ∆𝐴𝐴𝑇𝑇𝜀𝜀𝑇𝑇𝑆𝑆𝑆𝑆𝑆𝑆∆𝐴𝐴𝑇𝑇𝑆𝑆𝑆𝑆𝑆𝑆𝜀𝜀𝑇𝑇    (1.2) 
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where, ΦTStd is the triplet state quantum yield for the standard and 
unsubstituted ZnPc was used as a standard in DMSO (ΦTStd = 0.65) [167]. ∆𝐴𝐴𝑇𝑇 
and ∆𝐴𝐴𝑇𝑇𝑆𝑆𝑆𝑆𝑆𝑆 are the changes in the triplet state absorbance of the sample and 
the standard, respectively. 𝜀𝜀𝑇𝑇  and 𝜀𝜀𝑇𝑇𝑆𝑆𝑆𝑆𝑆𝑆 are the triplet state molar extinction 
coefficients for the sample and standard, respectively.  
To determine 𝜀𝜀𝑇𝑇   and 𝜀𝜀𝑇𝑇𝑆𝑆𝑆𝑆𝑆𝑆, the molar extinction coefficients of the ground 
singlet state of samples (𝜀𝜀S), standard (𝜀𝜀sstd) and the respective changes in 
triplet state absorbances of samples (Δ𝐴𝐴T) and standard ∆𝐴𝐴𝑇𝑇𝑆𝑆𝑆𝑆𝑆𝑆 are used 
according to equation 1.3 and 1.4. 
            𝜀𝜀𝑇𝑇 =  𝜀𝜀𝑠𝑠. Δ𝐴𝐴𝑇𝑇Δ𝐴𝐴𝑠𝑠                                       (1.3.) 
            𝜀𝜀𝑇𝑇𝑠𝑠𝑆𝑆𝑆𝑆 =  𝜀𝜀𝑠𝑠𝑠𝑠𝑆𝑆𝑆𝑆 . Δ𝐴𝐴𝑇𝑇𝑠𝑠𝑆𝑆𝑆𝑆Δ𝐴𝐴𝑠𝑠𝑠𝑠𝑆𝑆𝑆𝑆                                (1.4) 
The triplet lifetimes are obtained from the triplet decay curve by fitting using 
Origin Pro 8 software. 
 
1.4.3. Singlet oxygen quantum yield (Φ∆) 
Singlet oxygen (1O2) is a highly reactive oxygen species that is the primary 
cytotoxic agent in PDT [169]. It is formed through an energy transfer process 
between an excited triplet state of the MPc and ground state molecular oxygen 
(3O2), Figure 1.5.  
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The singlet oxygen generation may be experimentally determined by a 
chemical method that utilises singlet oxygen quenchers [170]. The singlet 
oxygen quenchers react with singlet oxygen (Scheme 1.4) as soon as it is 
produced in an oxygenated MPc solution. The depletion of the singlet oxygen 
quencher is spectroscopically monitored over predetermined time intervals to 
assess the singlet oxygen produced by the PS. Singlet oxygen quenchers such 
as 1,3 diphenylisobenzofuran (DPBF) or anthracene-9,10-bismethylmalonate 
(ADMA) (Scheme 1.4) can be used to quantify singlet oxygen production in 
organic solvents and aqueous solutions, respectively [171,172]  
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Scheme 1.4: Reaction of singlet oxygen with DPBF and ADMA. 
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The relative method is used for singlet oxygen quantum yield calculations, 
using equation 1.5.  
     ΦΔ = Φ𝛥𝛥
𝑆𝑆𝑆𝑆𝑆𝑆 𝑅𝑅 𝐼𝐼𝑎𝑎𝑎𝑎𝑠𝑠𝑆𝑆𝑆𝑆𝑆𝑆
𝑅𝑅𝑆𝑆𝑆𝑆𝑆𝑆  𝐼𝐼𝑎𝑎𝑎𝑎𝑠𝑠                                 (1.5) 
where Φ𝛥𝛥
𝑆𝑆𝑆𝑆𝑆𝑆 is the singlet oxygen quantum yield for the standard (ZnPc, Φ𝛥𝛥
𝑆𝑆𝑆𝑆𝑆𝑆 = 
0.67 in DMSO [172] or aluminium sulfonated phthalocyanine (AlPcSmix; 
mixture of sulfonated phthalocyanine derivatives), Φ𝛥𝛥
𝑆𝑆𝑆𝑆𝑆𝑆 = 0.42 in aqueous 
solutions) [173]. 
R and 𝑅𝑅𝑆𝑆𝑆𝑆𝑆𝑆 are the DPBF/ADMA photobleaching rates in the presence of the 
sample under investigation and the standard respectively. Iabs and 𝐼𝐼𝑎𝑎𝑎𝑎𝑠𝑠𝑆𝑆𝑆𝑆𝑆𝑆 are the 
rates of light absorption by the sample and the standard, respectively and are 
determined by equations 1.6 and 1.7 [174]. 
        𝐼𝐼𝑎𝑎𝑎𝑎𝑠𝑠 =  𝛼𝛼.Α.𝐼𝐼𝑁𝑁𝐴𝐴                                           (1.6) 
        𝐼𝐼𝑎𝑎𝑎𝑎𝑠𝑠𝑠𝑠𝑆𝑆𝑆𝑆 =  𝛼𝛼.Α.𝐼𝐼𝑁𝑁𝐴𝐴                                           (1.7) 
where α = 1-10-A(λ), A(λ) is the absorbance of the sensitizer at the illumination 
wavelength, A is the illuminated cell area (expressed in cm2), I is the intensity 
of light (expressed in photons cm-2s-1) and NA is the Avogadro's constant [173–
175] 
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1.5. Summary of aims  
The aims of this thesis include:   
•  Synthesis and characterization of symmetrical and asymmetrical, 
metallophthalocyanines with carboxyphenoxy, phenoxy propanoic acid, 
benzothiazole phenoxy, di-O-isopropylidene-α-D-glucopyranose and 
thiophine ethoxy as substituents. 
• Synthesis of nanoparticles (Ag1Au3NSs-GSH, Ag3Au1NSs-GSH, 
Ag3Au1SiNSs-APTES, AuNTs-GSH, AuNSs-GSH, AuNTs-CTAC, AuNSs-
CTAB, AuNRs-CTAB, AgNSs-GSH and GSS) and a AuCT composite. 
• Conjugation of metallophthalocyanines to nanoparticles, CT and a 
AuCT composite. 
• Study the spectroscopic (ground state electronic absorption, excitation 
and emission) properties of the synthesised MPcs when alone and when 
linked to NPs or CT or AuCT. 
• Study the photophysical (fluorescence quantum yield and lifetime, 
triplet quantum yield and lifetime) and photochemical (singlet oxygen 
quantum yield) properties of the synthesised MPcs when alone and 
when linked to NPs or CT or AuCT. 
• In vitro dark cytotoxicity and photodynamic therapy activities of 
selected MPcs and conjugates against MCF-7 breast cancer cells. 
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CHAPTER TWO 
 
 
2. Experimental Section 
 
This chapter gives details of the materials, instrumentation and experimental 
procedures used for the synthesis and characterisation of the complexes, 
nanoparticles, and their conjugates studied, together with in vitro dark 
cytotoxicity and PDT studies.   
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2.1 Materials  
2.1.1 Solvents 
Dimethyl sulfoxide (DMSO, spectroscopy grade), 1–pentanol, 1-choloro 
naphthalene, deuterated (DMSO-d6, chloroform-d), 1–hexanol and 25% 
ammonium hydroxide were obtained from Sigma Aldrich®. Absolute ethanol 
(EtOH), methanol (MeOH), dimethylformamide (DMF), cyclohexane, 
tetrahydrofuran (THF), nitric acid (55%), acetonitrile, acetone and toluene 
were obtained from SAARCHEM®. Ultra–pure water was obtained from a 
Milli–Q Water System (Millipore Corp, Bedford, MA, USA). 
 
2.1.2 Reagents 
Reagents for phthalonitrile precursors, phthalocyanines, nanoparticle 
syntheses and conjugation to NPs, chitosan and gold chitosan.  
3-(4-Hydroxyphenyl)-propionic acid, potassium carbonate, zinc(II) acetate 
dihydrate, indium(III) chloride, 1,8-diazobicylo[5.4.0]undec-7-ene   (DBU), 
unsubstituted zinc phthalocyanine (ZnPc), 1,2–dicyanobenzene, N,N’-
dicyclohexylcarbodiimide (DCC), 4-(dimethylamino)pyridine (DMAP), 1,3-
diphenylisobenzofuran (DPBF), chitosan (CT), silica gel, anthracene-9,10-bis-
methylmalonate (ADMA), glutathione (GSH), Triton X 100, tetraethyl 
orthosilicate (TEOS), gold(III) chloride trihydrate, silver acetate, (3–
aminopropyl)–triethoxysilane (APTES), diphenyl ether (DPE), potassium 
hydroxide pellets, oleylamine (OLA) and oleic acid (OA) were purchased from 
Sigma–Aldrich. The syntheses of 4-nitrophthalonitrile [176], 4-glycosylated 
phthalonitrile [80], 4-[4-(benzothiazol-2-yl)phenoxy] phthalonitrile  [39], 4-(2-
(2-thienyl)ethoxy)phthalonitrile [40]  and aluminium sulfonated 
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phthalocyanine (AlPcSmix- mixture of sulfonated phthalocyanine derivatives) 
[177] have been reported in the literature .  
 
Reagents for in vitro dark Cytotoxicity and PDT activity                   
Cultures of epithelial breast cancer cells (MCF-7 cells) were obtained from 
Cellonex. Trypsin ethylenediaminetetraacetic acid (EDTA), trypan blue, 
Dulbecco's phosphate-buffered saline (DPBS) and Dulbecco's modified Eagle's 
medium (DMEM) were obtained from Sigma Aldrich, heat-inactivated fetal calf 
serum (FCS), neutral red cell proliferation reagent (WST-1), and 100 µg/mL-
penicillin-100 unit/mL-streptomycin-amphotericin B mixture were obtained 
from Lonza (Biowest). 
 
2.2. Equipment 
i) Proton-nuclear magnetic resonance (1H NMR) spectra were 
recorded on a Bruker AVANCE II 600 MHz NMR spectrometer 
using tetramethylsilane (TMS) as an internal reference.  
ii) Elemental analyses of MPcs were carried out using a Vario-
Elementar Microcube ELIII CHNS instrument analyzer.  
iii) Mass spectra data were acquired on a Bruker AutoFLEX III Smart-
beam TOF/TOF mass spectrometer using α-cyano-4-
hydrocinnamic acid as the matrix.  
iv) Infrared spectra were acquired on a Bruker ALPHA FT–IR 
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spectrometer with universal attenuated total reflectance (ATR) 
sampling accessory. 
v) Ground state electronic absorption was measured using a 
Shimadzu UV-2550 spectrophotometer.  
vi) Fluorescence excitation and emission spectra were measured on a 
Varian Eclipse spectrofluorimeter using a 360–1100 nm filter. 
Excitation spectra were recorded at the wavelength of the emission 
maxima. 
vii) Fluorescence lifetimes were measured using a time correlated 
single photon counting setup (TCSPC) (FluoTime 300, Picoquant 
GmbH) with a diode laser (LDH-P-670, Picoquant GmbH, 20 MHz 
repetition rate, 44 ps pulse width). Fluorescence was detected 
under the magic angle with a peltier cooled photomultiplier tube 
(PMT) (PMA-C 192-N-M, Picoquant GmbH) and integrated 
electronics (PicoHarp 300E, Picoquant GmbH).  A monochromator 
with a spectral width of about 4 nm was used to select the required 
emission wavelength. The response function of the system, which 
was measured with a scattering Ludox solution (DuPont), had a 
full width at half-maximum (FWHM) of about 300 ps. The ratio of 
stop to start pulses was kept low (~0.05) to ensure good statistics. 
All fluorescence decay curves were measured at the wavelength of 
emission maxima. The data were analysed with the FluoFit 
software (Picoquant®). The support plane approach was used to 
estimate the errors of the decay times [178]. The layout of the 
TCSPC is shown in Figure 2.1. 
45 
 
 
Figure 2.1: Schematic representation of time correlated single photon 
counting (TCSPC) set–up. (MCP)–PMT = (Multichannel plate detector) 
Monochromator Photomultiplier Tube 
 
viii) A laser flash photolysis system was used to determine the triplet 
quantum yields. The excitation pulses were produced using a 
tunable laser system consisting of an Nd:YAG laser (355 nm, 135 
mJ/4–6 ns) pumping an optical parametric oscillator (OPO, 30 
mJ/3–5 ns) with a wavelength range of 420–2300 nm (NT-342B, 
Ekspla, Figure 2.2). The signal from a PMT detector was recorded 
on an oscilloscope. A new system consisting a LP980 spectrometer 
with a PMT-LP detector, Tektronix digital storage oscilloscope and 
an ICCD camera (Andor DH320T-25F03) was also used, Figure 2.3.  
 
The absorbance of the sample solution and the standard were ~1.5 
at the Q–band. The solution was introduced into a 1 cm path 
length quartz cell and deaerated using argon for 10 min. 
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Thereafter the solution was sealed and illuminated using an 
appropriate excitation wavelength source (the crossover 
wavelength of the sample and the standard is utilized as the laser 
excitation source wavelength). The maximum triplet absorption 
detection wavelength was determined from the transient curve.  
The triplet lifetimes were determined by exponential fitting of the 
kinetic curves using OriginPro® 8 software.  
 
 
Figure 2.2: Schematic diagram for a laser flash photolysis set–up (old 
system). 
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Figure 2.3: Schematic diagram for a LP980 laser flash photolysis set–up 
(new system; insert shows the LP980 laser flash photolysis spectrometer). 
 
ix) Irradiation for singlet oxygen quantum yield was performed using 
a general electric quartz lamp (300 W) as irradiation source.  A 
600 nm cut-off glass filter (Schott) for ultra violet radiation and a 
water filter for infrared radiation were used. An interference filter, 
670 nm with a band of 40 nm was additionally used before the 
sample chamber. Light intensity was measured with a POWER 
MAX 5100 (Molelectron detector incorporated) power meter. 
Solutions of photosensitizer containing DPBF in DMSO or ADMA 
in aqueous media, were prepared in the dark and irradiated in the 
Q-band region. DPBF and ADMA degradation at 417 nm and 380 
respectively, was monitored during irradiation to quantify the 
singlet oxygen quantum yield with reference to a standard. The 
layout of the photochemical set–up is shown in Figure 2.4. 
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Figure 2.4: Schematic illustration of photochemical set–up 
 
x) X-ray powder diffraction (XRD)  patterns were recorded using a Cu 
kα radiation (1.5405˚A, nickel filter), on a Bruker D8 Discover 
equipped with a proportional  counter. Scanning was at 10 min-1 
with a filter time-constant of 2.5 s per step and a slit width of 6.0 
nm. The data were obtained in the range from 2θ = 5°to 100°. A 
zero background silicon wafer slide was used for sample 
placement. The data analysis was carried out using Eva 
(evaluation curve fitting) software. Subtraction of spline fitted to 
the curved background was used for baseline correction of each 
diffraction pattern and the full-width at half maximum value was 
obtained from the fitted curve. 
xi) Transmission electron microscope (TEM) images were obtained 
using a ZEISS LIBRA model 120 operated at 90 kV and iTEM 
software was used for TEM micrographs processing. 
xii) Dynamic light scattering (DLS) experiments were done on a Malvern 
Zetasizer nanoseries, Nano-ZS90. 
xiii) The X-ray photoelectron spectroscopy (XPS) data were acquired 
using a Kratos Axis Ultra DLD spectrometer, with an Al 
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(monochromatic) anode, equipped with charge neutralizer and the 
operating pressure was kept below 5 ×10-9 torr. The resolution was 
10 eV pass energy in the slot mode. For the XPS wide scan, the 
following parameters were used: emission current was kept at 12.5 
mA and the anode (HT) voltage at 15 kV. The resolution was 
maintained at 160 eV pass energy using a hybrid lens in the slot 
mode. For the high-resolution scans, the resolution was changed to 
40 eV pass energy in the slot mode. 
xiv) Illumination for PDT studies of Pcs and conjugates were performed 
using a Modulight Medical Laser system (ML) 7710-680 channel 
Turnkey laser system coupled with 2 × 3W channels at 680 nm, 
cylindrical output channels, aiming beam, integrated calibration 
module, foot/hand switch pedal, fibre sensors (subminiature version 
A) connectors and safety interlocks. The iIllumination kit for in vitro 
PDT studies with capacity to hold 127.76 × 85.48 mm 96 well tissue 
culture plate was used. 
xv) The MCF-7 cells were cultured in a humidified atmosphere incubator 
with ~5% CO2 and temperature at 37 °C (Heal Force).  
xvi) The cells were viewed under phase contrast using a Zeiss 
AxioVert.A1 Fluorescence LED (FL-LED) inverted microscope. 
xvii) The cell viability was measured with Synergy 2 multi-mode 
microplate reader (BioTek). 
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2.3. Synthesis of phthalonitrile and phthalocyanines  
One phthalonitrile and six MPcs are reported here for the first time and their 
synthetic details are provided in this section. Details for the already known 
phthalonitriles (4-glycosylated phthalonitrile [80], 4-[4-(benzothiazol-2-
yl)phenoxy] phthalonitrile [39], 4-[2-(2-thienyl)ethoxy] phthalonitrile [40]) and 
MPcs (indium(III) tetra–(3–carboxyphenoxy) phthalocyanine (1) [37], zinc(II) 
tetra-(benzothiazol-2-yl phenoxy) phthalocyanine (3a) [38], indium(III) 
chloride tetra-(benzothiazol-2-yl phenoxy) phthalocyanine (3b) [39] and 
zinc(II) tetra-(thiophine ethoxy) phthalocyanine (4a) [40]) are as reported in 
literature.  
 
2.3.1. Synthesis of 4-[3-(4-phenoxy)propanoic acid] phthalonitrile, 
Scheme 3.1.  
3-(4-Hydroxyphenyl) propionic acid (1.44 g, 8.66 mmol) and 4-
nitrophthalonitrile (1.5 g, 8.66 mmol) were dissolved in DMF (20 mL) under 
nitrogen atmosphere and the mixture was stirred at room temperature for 15 
min. Finely ground K2CO3 (2.11g,15.31 mmol) was added thereafter, and the 
reaction mixture was left to stir for a further 36 h at room temperature. The 
mixture was then added to ice water (150 mL). The resulting precipitate was 
ﬁltered off, thoroughly washed with water, dried and recrystallized from 
ethanol to give 4-[3-(4-phenoxy)propanoic acid] phthalonitrile. Yield: 2.24g 
(89%). IR [cm-1]: 3300 (COOH) 2890-3030 (C–H), 2230 (C≡N), 1668-1583 
(C=C), 1437-1387 (C–O), 1322-1275 (C-O), 1228 (Ar-O-Ar). 1H NMR (DMSO–
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d6): δ, ppm 7.89 (d, J = 7.52 Hz, 1H, Ar–H), 7.56 (d, J = 7.35 Hz, 1H, Ar–H), 
7.37 – 7.32 (m, 3H, Ar–H), 7.12 (m, 2H, Ar–H), 3.48 (s, 1H, OH), 2.85 (t, J = 
5.17 Hz, 2H, CH2), 2.55 (t, J = 6.54 Hz, 2H, CH2). Anal. Calc. for (C17H12N2O3): 
C, 69. 86; H, 4.14; N, 9.58. Found: C, 68.69: H, 3.89; N, 9.87. 
 
2.3.2. Synthesis of zinc(II) tetra–[3–(4–phenoxy) propanoic acid] 
phthalocyanine (2), Scheme 3.2. 
A mixture of 4-[3-(4-phenoxy)propanoic acid] phthalonitrile (0.25 g, 0.86 
mmol), dry 1–pentanol (3 mL), zinc(II) acetate dihydrate (0.25 g, 1.1 mmol) 
and DBU (0.3 mL) was transferred into a round bottom flask. The reaction 
mixture was refluxed at 180 °C for 6 h with constant stirring in the presence 
of nitrogen. After 6 h, the product was cooled to room temperature, washed 
successively under centrifugation with methanol. The product, zinc(II) tetra–
[3–(4–phenoxy) propanoic acid] phthalocyanine (2) was dried under vacuum 
and purified by column chromatography (silica gel, THF-methanol, 9:1). Yield: 
0.46g (43%). IR (cm-1): 3420 (COOH), 2954 (C–H), 1603-1554 (C=C), 1431-
1401 (C–O), 1225 (Ar-O-Ar). UV/Vis (DMSO), λmax (nm) (log ε): 680 (4.80), 613 
(4.08), 367 (4.50). 1H NMR (600 MHz, DMSO-d6) δ 8.89 (s, 3H, Ar-H), 8.57 – 
8.25 (s, 3H, Ar-H), 7.78 – 7.57 (m, 3H, Ar-H), 7.58 – 7.28 (m, 17H, Ar-H), 7.19 
– 7.05 (m, 2H, Ar-H), 4.02 – 3.50 (s, 4H, H from COOH), 3.07 – 2.85 (m, 8H, 
CH2), 2.98 – 2.67 (m, 8H, CH2). Anal. Calc. for (C68H48N8O12Zn): C, 66.16; H, 
3.92; N, 9.08. Found: C, 65.21: H, 3.56; N, 8.09. MS (MALDI-TOF) m/z: Calcd: 
1234.54; Found: 1234.23 [M]+. 
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2.3.3. Synthesis of indium(III) chloride tetra-(thiophine ethoxy) 
phthalocyanine (4b), Scheme 3.3. 
Indium(III) chloride tetra-(thiophine ethoxy) phthalocyanine was synthesised 
in two steps; the first step was the synthesis of the metal-free phthalocyanine 
(H2Pc) derivative and the second step involves the metalation of the H2Pc. The 
synthesis of the H2Pc is as follows: 4-[2-(2-thienyl) ethoxy] phthalonitrile (0.58 
g, 2.28 mmol) was dissolved in dry 1-pentanol (4 mL), in the presence of DBU 
(0.3 mL, mmol). The reaction mixture was refluxed at ~140 °C for 6 h with 
constant stirring under nitrogen atmosphere. On cooling the product to room 
temperature, methanol was added to the crude product and centrifuged. The 
washing with methanol was repeated successively until a pure metal free 
compound was obtained (H2Pc). 
Yield: 0.45 g (77%). IR [νmax/cm-1]: 3073 (Ar-H), 2923 (C-H stretch), 1654, 
1600 (C=C), 1513, 1352, 1226 (Ar-O-Ar). UV/Vis (DMSO), λmax nm: 706, 673, 
645, 616, 392, 343. 1H NMR (600 MHz, DMSO-d6) δ 8.95 (d, J = 8.12 Hz, 3H, 
Ar-H), 8.54 (d, J = 6.62 Hz, 3H, Ar-H), 7.61 – 7.04 (m, 18H, Ar-H), 4.72 (t, J = 
4.88 Hz, 8H, CH2), 4.32 (s, 2H, NH), 3.59 (t, J = 5.67 Hz 8H, CH2). Anal. Calc. 
for (C56H42N8O4S4): C, 65.99; H, 4.15; N, 10.99; S, 12.58. Found: C, 66.54: H, 
3.98; N, 10.78; S, 13.03. MS (MALDI-TOF) m/z: Calcd: 1019.24; Found: 
1019.30 [M]+. 
The conversion of the H2Pc to an MPc was achieved by mixing the H2Pc (0.20 
g, 1.96 mmol) with indium chloride (0.20 g, 0.90 mmol) in 5 mL 1-
chloronaphthalene) and heating at ~ 100 °C for 5 h. Upon cooling the product 
to room temperature, methanol was added, and the resulting precipitate 
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centrifuged, and washed several times with methanol. The product indium(III) 
chloride tetra-(thiophine ethoxy) phthalocyanine (4b) was dried under 
vacuum and purified by column chromatography (silica gel, THF-methanol, 
9:1).  
Indium(III) chloride tetra-(thiophine ethoxy) phthalocyanine (4b): Yield: 0.15g 
(75%). IR [νmax/cm-1]: 3069 (Ar-H), 2921 (C-H stretch), 1599 (C=C), 1515, 
1348, 1228 (Ar-O-Ar). UV/Vis (DMSO), λmax nm (log ε): 696 (4.89), 627 (4.43), 
332 (4.55). 1H NMR (600 MHz, DMSO-d6) δ 8.99 (d, J = 7.83 Hz, 3H, Ar-H), 
8.54 (d, J = 6.69 Hz, 3H, Ar-H) , 7.67 – 7.08 (m, 18H, Ar-H), 4.75 (t, J = 5.42 
Hz, 8H, CH2), 3.52 (t, J = 5.99 Hz 8H, CH2). Anal. Calc. for (C56H40ClInN8O4S4): 
C, 57.61; H, 3.45; N, 9.60; S, 10.99. Found: C, 57.94: H, 3.63; N, 9.51; S, 
10.69. MS (MALDI-TOF) m/z: Calcd: 1167.50; Found: 1167.26 [M]+. 
 
2.3.4. Zinc(II) mono–[3–(4–phenoxy) propanoic acid] phthalocyanine (5), 
Scheme 3.2. 
A mixture of 4-[3-(4-phenoxy)-propanoic acid] phthalonitrile (0.20 g, 0.68 
mmol), 1,2-dicyanobenzene (0.44 g, 3.42 mmol), zinc(II) acetate dihydrate 
(0.25 g, 1.1 mmol) and DBU (0.3 mL), dissolved in dry 1-pentanol (3 mL) was 
refluxed at 180 °C with constant stirring, in the presence of nitrogen for 6 h. 
The product was cooled and washed with methanol several times. Column 
chromatography was done over silica with THF: methanol (9:1) as an eluent. 
Several fractions were collected until zinc(II) mono-[3-(4-phenoxy)propanoic 
acid] phthalocyanine (5) was obtained. 
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Yield: 0.67g. IR [νmax/cm-1]: 3204-3020 (COOH), 2912 (C-H stretch), 1701 (-
C=O), 1596 (C=C), 1471-1398 (C–OH), 1223 (Ar-O-Ar). UV/Vis (DMSO), λmax 
nm (log ε): 675 (4.90), 608 (4.46), 356 (4.70). 1H NMR (600 MHz, DMSO-d6) δ 
8.25 – 8.03 (d, J = 7.87 Hz,  2H, Ar-H), 7.80 – 7.62 (d, J = 7.73 Hz, 2H, Ar-H), 
7.5 – 7.25 (m, 9H, Ar-H), 7.24 – 7.04 (m, 6H, Ar-H), 3.55 – 3.27 (s, 1H, H from 
COOH), 2.89 (t, J = 5.47 Hz, 2H, CH2), 2.73 (t, J = 6.21 Hz, 2H, CH2). Anal. 
Calc. for (C41H24N8O3Zn): C, 66.36; H, 3.26; N, 15.10. Found: C, 65.42: H, 
2.89; N, 15.02. MS (MALDI-TOF) m/z: Calcd: 742.06; Found: 743.19 [M+H]+. 
 
2.3.5. Zinc(II) [tris-(4-(benzothiazol-2-yl)phenoxy)- 3-(4-
phenoxy)propanoic acid] phthalocyanine (6), Scheme 3.4. 
A mixture of 4-[4-(benzothiazol-2-yl)phenoxy] phthalonitrile 0.64g, 1.73 
mmol), 4-[3(4-phenoxy)propanoic acid] phthalonitrile (0.10 g, 0.33 mmol) and 
zinc(II) acetate dihydrate (0.23 g, 1.1 mmol) was dissolved in dry 1-pentanol 
(7 mL), after which DBU (0.4 mL) was added. The reaction mixture was 
refluxed at ~140 °C with constant stirring for 6 h, under nitrogen atmosphere. 
The crude product was cooled to room temperature and precipitated out of 
solution using methanol. The precipitate was successively purified with 
methanol under centrifugation, dried under vacuum and finally purified by 
column chromatography (silica gel, THF-pentane, 4:1).  
Zinc(II) [tris(4-(benzothiazol-2-yl)phenoxy)- 3-(4-phenoxy)propanoic acid] 
phthalocyanine (6): Yield: 0.14 g (19%), IR [νmax/cm-1]: 3049 (OH), 2942 (C-H 
stretch), 1715 (C=O), 1596 (C=C), 1470, 1327, 1223 (Ar-O-Ar). UV/Vis 
(DMSO), λmax nm (log ε): 680 (4.89), 612 (4.26), 341 (4.60). 1H NMR (600 MHz, 
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DMSO-d6) δ 12.27 (s, 1H, OH), 8.82 (m, 4H, Ar-H), 8.34 (m, 4H, Ar-H), 8.11 – 
8.06 (m, 6H, Ar-H), 7.82-7.73 (dd, J = 14.5, 8.7 Hz, 6H, Ar-H), 7.54-7.35 (m, 
16H, Ar-H), 6.89 (s, 3H, Ar-H ), 6.70 (s, 1H, Ar-H), 4.07 (t, J = 6.1 Hz, 2H, 
CH2), 3.02 (t, J = 5.8 Hz, 2H, CH2). Anal. Calc. for (C80H45N11O6S3Zn): C, 67.77; 
H, 3.20; N, 10.87; S, 6.78. Found: C, 67.84: H, 3.42; N, 10.51; S, 7.02. MS 
(MALDI-TOF) m/z: Calcd: 1417.86; Found: 1416.74 [M-H]+. 
 
2.3.6. Zinc(II) [tris-(3-(4-phenoxy)propanoic acid)-4-(bezothiazol-2-yl) 
phenoxyl] phthalocyanine (7), Scheme 3.4. 
A mixture of 4-[4-(benzothiazol-2-yl)phenoxy] phthalonitrile (0.11g, 0.31 
mmol), 4-[3-(4-phenoxy)propanoic acid] phthalonitrile (0.46 g, 1.56 mmol) 
and zinc(II) acetate dihydrate (0.20 g, 0.96 mmol) was dissolved in dry 1-
pentanol (4 mL), after which DBU (~0.1 mL) was added. The reaction mixture 
was refluxed at 160 °C for 6 h, under nitrogen atmosphere. On cooling, 
methanol was added and the precipitate was collected under centrifugation. 
The precipitate was successively purified with methanol under centrifugation, 
dried and further purified by column chromatography using THF and 
methanol (9:1) as eluent, yielding zinc(II) [tris-(3-(4-phenoxy)propanoic acid)-
4-(bezothiazol-2-yl) phenoxyl] phthalocyanine (7). 
Yield: 0.08g (14.0%). IR [νmax/cm-1]: 3065 (OH), 2921 (C-H stretch), 1719 
(C=O), 1596, 1475 (C=C), 1230 (Ar-O-Ar). UV/Vis (DMSO), λmax nm (log ε): 681 
(4.85), 614 (4.16), 356 (4.48). 1H NMR (600 MHz, DMSO-d6) δ 11.32 (s, 3H, 
OH), 7.81 (d, J = 8.8 Hz, 2H, Ar-H), 7.37−7.09 (m, 30H, Ar-H), 2.89−2.85 (dd, 
J = 6.9, 1.5 Hz, 6H, CH2), 2.68−2.65 (t, J = 5.7 Hz, 6H, CH2), Anal. Calc. for 
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(C72H47N9O10SZn): C, 66.74; H, 3.66; N, 9.73; S, 2.47. Found: C, 66.29: H, 
3.89; N, 9.41; S, 3.00. MS (MALDI-TOF) m/z: Calcd: 1295.64; Found: 1295.40 
[M]+. 
 
2.3.7. Zinc(II) [(tris- (2,2,7,7-tetramethyltetrahydro-3aH-bis([1,3] 
dioxolo)[4,5-b:4',5'-d]pyran-5-yl)methoxy)-2-(4-benzothiazol-2-yl)phenoxy] 
phthalocyanine (8), Scheme 3.5. 
A mixture of 4-glycosylated phthalonitrile (0.55 g, 1.42 mmol), 4-[4-(benzo 
thiazol-2-yl)phenoxy] phthalonitrile (0.1 g, 0.28 mmol), zinc(II) acetate 
dihydrate (0.25 g, 1.1 mmol) and DBU (0.3 mL), was dissolved in dry 1-
pentanol (3 mL). The reaction mixture was refluxed at 180 °C with constant 
stirring, in the presence of nitrogen for 6 h. The product was cooled to room 
temperature and successively precipitated out of solution using methanol. 
Zinc(II) [tris- (2,2,7,7-tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-
d]pyran-5-yl)methoxy)-2-(4-(benzothiazol-2-yl)phenoxy] phthalocyanine (8) 
was obtained using silica packed column chromatography with THF:methanol 
(9:1) as an eluent.  
Yield: 0.11 g (16.9%). IR [νmax/cm-1]: 3196, 2921 (C-H stretch), 1710, 1605 
(C=C), 1474-1371 (C=C), 1217 (Ar-O-Ar). UV/Vis (DMSO), λmax nm (log ε): 682 
(5.55), 612 (4.52), 320 (4.78). 1H NMR (400 MHz, CDCl3) δ 8.13 (d, J = 8.7 Hz, 
2H), 8.02 (d, J = 8.1 Hz, 1H), 7.87 (d, J = 7.8 Hz, 1H), 7.71 (d, J = 8.7 Hz, 1H), 
7.64 (d, J = 8.8 Hz, 2H), 7.52 – 7.41 (m, 1H), 7.39 – 7.29 (m, 3H), 7.25 (dd, J 
= 8.9, 2.5 Hz, 3H), 7.16 (dd, J = 10.8, 5.7 Hz, 6H), 5.50 (d, J = 5.0 Hz, 6H), 
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4.61 (dd, J = 7.9, 2.5 Hz, 6H), 4.33 – 4.09 (m, 9H), 1.44 (m, 24H), 1.29 (s, 
12H). Anal. Calc. for (C81H77N9O19SZn): C, 61.65; H, 4.92; N, 7.99; S, 2.03. 
Found: C, 62.02: H, 5.09; N, 7.02; S, 1.92. MS (MALDI-TOF) m/z: Calcd: 
1577.97; Found: 1578.44 [M + H]+. 
 
2.4. Synthesis of nanoparticles (NPs) and composites. 
The syntheses of GSH capped AgNSs-GSH [179], AuNSs-GSH [180], as well 
as the CTAB capped AuNSs-CTAB, AuNRs-CTAB [181] and CTAC capped 
AuNTs-CTAC [182] have been reported before. CTAC was chosen as a capping 
agent over CTAB for the synthesis of nanotriangles since it results in a high 
yield [182].  
 
2.4.1. Synthesis glutathione (GSH) functionalized AgxAuy alloy and 
AuNTs nanoparticles.  
Firstly oleic acid/oleylamine (OA/OLA) capped AgxAuy alloys with different 
mole ratios (3:1 and 1:3) were synthesised as reported in literature with 
modifications [122]. For the formation of Ag3Au1 (this is a Ag rich alloy), a 
mixture of silver acetate (0.38 g, 2.26 mmol) and gold(III) chloride trihydrate 
(0.251 g, 0.74 mmol) was employed. For the formation of Ag1Au3 (this is an 
Au rich alloy), a mixture of silver acetate (0.062 g, 0.37 mmol) and gold(III) 
chloride trihydrate (0.38 g, 1.11 mmol) was employed. The mixtures above 
were separately placed into 250 mL round bottom flasks containing diphenyl 
ether (DPE, 30 g, 176.3 mmol), oleylamine (OLA, 10 mL) and oleic acid (OA, 5 
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mL). The reaction mixtures were refluxed at 160 °C and maintained under 
argon atmosphere for 5 h, followed by cooling to room temperature. The 
products were successively purified with ethanol and dried in enclosed fume 
hood and are represented as Ag3Au1NSs-OA/OLA and Ag1Au3NSs-OA/OLA  
The surface of Ag3Au1NSs-OA/OLA, Ag1Au3NSs-OA/OLA and AuNTs-CTAC 
were separately modified with glutathione (GSH) as follows: Ag3Au1NSs-
OA/OLA, Ag1Au3NSs-OA/OLA and AuNTs-CTAC (0.40 g) were each 
transferred into separate round bottom flasks containing cyclohexane (3 mL). 
A solution containing methanol (20 mL), GSH (0.25 g, 0.81 mmol) and KOH 
(0.50 g, 8.93 mmol) was added to the NPs mixture. The mixtures were stirred 
for 2 h at room temperature. Afterwards, the formed GSH capped NPs were 
precipitated out of solution using ethanol and purified with methanol. The 
obtained solid precipitates were air dried in an enclosed fume hood. The 
nanoparticles are represented as Ag3Au1NSs-GSH, Ag1Au3NSs-GSH and 
AuNTs-GSH.  
 
2.4.2. Doping of Ag3Au1NSs-OA/OLA into SiNSs to form Ag3Au1SiNSs-
APTES, Scheme 3.6B. 
The doping of the Ag3Au1NSs-OA/OLA into SiNSs was done using a method 
adopted from literature [183] as follows: Triton X–100 (1.80 mL), 1–hexanol 
(1.80 mL) and cyclohexane (7.5 mL) were introduced into a 50 mL round 
bottom flask and stirred for 20 min. Afterwards 0.20 g of Ag3Au1NSs-OA/OLA 
in cyclohexane was added and the mixture was further stirred for 10 min. 
TEOS (0.15 mL) was then added, followed by dropwise addition of H2O (0.4 
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mL) and 25% NH3OH solution (0.06 mL) for 1 h. The mixture was kept stirring 
for 24 h to allow for nucleation and particle growth of the SiNSs around 
Ag3Au1NSs to form Ag3Au1SiNSs. The obtained product was isolated out of 
solution using ethanol, purified with ethanol and air dried in an enclosed 
fume hood. 
The functionalisation of the Ag3Au1SiNSs using APTES was done as reported 
in the literature [184] with modifications. Briefly, 0.09 g of Ag3Au1SiNSs was 
weighed into a 50 mL round bottom flask, then, APTES (0.2 mL, 0.85 mmol) 
and toluene (2 mL) were added. The mixture was refluxed at 110 °C for 5 h. 
The obtained product was purified with ethanol and acetonitrile. Finally, the 
solid was air dried in an enclosed fume hood. The product is represented as 
Ag3Au1SiNSs-APTES. 
 
2.4.3. Synthesis of gold-speckled silica (GSS) nanoparticles, Scheme 
3.7.  
Gold-speckled silica (GSS) nanoparticles were synthesized using 3-
aminopropyl)-triethoxysilane (APTES) functionalised silica nanoparticles 
(SiNSs-APTES) [183,184] and gold nanoparticles seeds [185] which were 
synthesized as reported in the literatures with slight modifications. For the 
attachment of gold nanoparticles seeds onto functionalized silica cores, 40 mg 
of APTES functionalized silica nanoparticles were dispersed in THF and placed 
in a 150 ml flask with an excess of gold nanoparticles seeds. The mixture was 
stirred gently for 5 min and then allowed to stand for 2h. The mixture was 
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then centrifuged, washed with water and the gold decorated SiNSs (GSS) were 
dried. 
 
2.4.4. Synthesis of a gold chitosan (AuCT) composite, Scheme 3.8.  
A gold-chitosan (AuCT) composite [186,187] was prepared as reported in the 
literature with slight modifications; briefly CT (100 mg) was dissolved in 1% 
(v/v) aq. solution of acetic acid (40 mL) and stirred for 1 h at room temperature 
until a homogeneous viscous solution was obtained. The aqueous CT solution 
(20 mL) was then added to an excess solution of gold nanoparticles seeds 
synthesized as reported in literature [185], followed by stirring at room 
temperature for 24 h. The obtained product (AuCT) was successively washed 
with acetone and centrifuged until a clear supernatant was observed. 
 
2.5. Conjugation of MPcs to NPs and composites. 
2.5.1. Covalent (amide bond) linkage of complexes to GSH or APTES 
functionalised NPs, Scheme 3.9.  
The MPc–NPs conjugates were synthesized as follows: complex 1 (0.02 g, 
0.017 mmol), complex 2 (0.02 g, 0.017 mmol), complex 5 (0.013 g, 0.017 
mmol), complex 6 (0.023 g, 0.016 mmol) and complex 7 (0.022 g, 0.017 mmol) 
were dissolved in 2 mL of dry DMF. The coupling agents, DCC (0.01 g, 0.049 
mmol) and DMAP (0.005 g, 0.042 mmol) were added to activate the carboxylic 
acid group of the MPc complexes to allow for covalent linkage to NPs via amide 
bond formation. The reaction was stirred for 48 h at room temperature after 
which 0.05 g of NPs (either Ag1Au3NSs-GSH, Ag3Au1NSs-GSH, Ag3Au1SiNSs-
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APTES, AuNSs-GSH, AgNSs-GSH or AuNTs-GSH) was added and the reaction 
mixture was stirred for further 48 h at room temperature (Scheme 3.9, 
complex 1 as a representative). The conjugates formed were centrifuged, 
successively purified with ethanol and allowed to dry in the fume hood. The 
conjugates are represented as 1-Ag1Au3NSs-GSH, 1-Ag3Au1NSs-GSH, 1-
Ag3Au1SiNSs-APTES, 2-AuNSs–GSH, 2-AgNSs–GSH, 2-AuNTs-GSH, 2-
Ag3Au1NSs–GSH, 5-AuNSs–GSH, 5-AgNSs–GSH, 5-AuNTs-GSH, 5-
Ag3Au1NSs–GSH, 6-AuNTs–GSH, 6-AuNSs–GSH, 7-AuNTs–GSH and 7-
AuNSs–GSH) 
 
2.5.2. Linkage (Au-S/Au-N) of complexes 3a, 3b, 4a, 4b, 6, 7 and 8 to 
AuNPs, Scheme 3.10. 
The presence of gold in AuNPs, is expected to foster the formation of sulphur-
gold (Au-S) or nitrogen-gold (Au-N) bonds between NPs and complexes, 
through self-assembly since the thiophine portion of complexes 4a and 4b 
contain sulphur while the benzothiazole in complexes 3a, 3b, 6, 7 and 8 
contains both sulphur and nitrogen groups.  
The MPcs were linked to AuNSs-CTAB, AuNTs-CTAC and AuNRs-CTAB (for 
complex 8 only) as follows: complex 3a (0.02 g, 0.014 mmol), complex 3b (0.02 
g, 0.013 mmol), complex 4a (0.021 g, 0.019 mmol), complex 4b (0.02 g, 0.017 
mmol), complex 6 (0.02g, 0.014 mmol), complex 7 (0.02 g, 0.015 mmol) and 
complex 8 (0.02g, 0.0127mmol) were separately dissolved in dry DMF (2 mL) 
and 0.5 mg of NPs (AuNSs-CTAB or AuNTs-CTAC or AuNRs-CTAB) in 3 mL 
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water were added and the reaction mixture was stirred for 24 h at room 
temperature (Scheme 3.10, shows the linkage of complex 8 to AuNSs-CTAB 
as a representative).  
The conjugates were centrifuged, successively washed with ethanol and 
allowed to dry in the fume hood. The conjugates are represented as 3a-AuNSs-
CTAB, 3a-AuNTs-CTAC, 3b-AuNSs-CTAB, 3b-AuNTs-CTAC, 4a-AuNSs-
CTAB, 4a-AuNTs-CTAC, 4b-AuNSs-CTAB, 4b-AuNTs-CTAC, 6-AuNSs-CTAB, 
6-AuNTs-CTAC, 7-AuNTs-CTAC, 8–AuNSs-CTAB and 8–AuNRs-CTAB 
 
2.5.3. Linkage of complexes 3a, 3b, 4a and 4b to gold-speckled silica 
NPs, Scheme 3.7. 
The MPc–GSS conjugates were synthesized as follows: complex 3a (0.02 g, 
0.014 mmol), complex 3b (0.02 g, 0.013 mmol), complex 4a (0.02 g, 0.018 
mmol) or complex 4b (0.02 g, 0.017 mmol) were separately dissolved in dry 
DMF (2 mL). GSS (0.05 g in 5 mL DMF) were added and the reaction mixture 
was stirred for 24 h at room temperature (Scheme 3.7, shows the linkage of 
complex 4b to GSS as a representative). The conjugates were centrifuged, 
successively purified with ethanol and allowed to dry in the fume hood. The 
conjugates are represented as 3a-GSS, 3b-GSS, 4a-GSS and 4b-GSS. 
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2.5.4. Linkage of complex 6 to CT and AuCT, Scheme 3.8. 
The CT composites were prepared as beads using the reported coacervation 
precipitation method reported previously [120] with slight modifications. 
Briefly complex 6 (0.02g, 0.014 mmol) in DMF (5 mL) was mixed with CT 
(0.024 g in 10 mL of 1% (v/v) aqueous acetic acid solution) or AuCT (0.047 g 
in 10 mL of 1% (v/v) aqueous acetic acid solution). The mixtures were stirred 
for 48 h at room temperature. The conjugates were successively purified with 
ethanol under centrifugation and allowed to dry in the fume hood. The 
conjugates are represented as 6-CT and 6–AuCT. 
 
 
2.6 In vitro dark cytotoxicity and photodynamic therapy studies.                   
The in vitro dark cytotoxicity and PDT studies of complex 3b, 3b-GSS and 
GSS; complex 6, 6-AuCT and AuCT; complex 8, 8-AuNSs-CTAB, 8-AuNRs-
CTAB, AuNSs-CTAB and AuNRs-CTAB were tested against epithelial breast 
cancer cell lines (MCF–7). Complexes and some conjugates are not soluble in 
aqueous media, hence they were first dissolved in DMSO and made up to the 
desired volume with supplemented DMEM.  
 
2.6.1. Culturing of MCF–7 cells. 
The MCF–7 cells were cultured using Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 10% (v/v) heat inactivated fetal calf serum (FCS) 
and 100 unit/mL penicillin–100 µg/mL streptomycin–amphotericin B. The 
cells were cultured in T75 flasks, incubated at 37 °C and 5% CO2 in a 
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humidified atmosphere until a cell confluence of 80 % was achieved.  The cells 
were rinsed with Dulbecco's modified phosphate buffer saline (DPBS) before 
routine trypsinisation. The viable trypsinised cells were counted with the aid 
of a trypan blue dye exclusion assay (0.40% trypan blue solution) using a 
hemocytometer. The cells were seeded at a cell density of 10,000 cells/well in 
supplemented DMEM containing phenol red in 96–well plates.  They were 
further   incubated under similar conditions for 24 h to allow cell attachment 
to the wells. The attached cells were rinsed with 100 µL DPBS once, followed 
by administration of 100 µL supplemented DMEM containing gradient doses 
of the respective drugs (complexes, conjugates and NPs). The stock drug 
concentrations were prepared in DMSO and made up to the desired volume 
with supplemented DMEM. Plates were re-incubated again at 37°C and 5% 
CO2 in the dark for 24 h. The effect of DMSO on the cells was investigated by 
the incubation of cells with 1.6% (v/v) DMSO in supplemented DMEM which 
represents the highest percentage of DMSO in the drug gradient solutions. 
Control cells were given supplemented DMEM with phenol red without the 
drug. After 24 h, the cells were rinsed with 100 µL DPBS once and were ready 
for in vitro dark cytotoxicity  
 
2.6.2. In vitro dark cytotoxicity and PDT activity.   
For in vitro dark toxicity supplemented DMEM with phenol red was added and 
the plates were re-incubated for 24 h.  
For PDT studies, supplemented phenol red free DMEM was added and the 
plates were subsequently illuminated with fixed light dosimetry of 170 J/cm2 
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using a Modulight ML7200 series illumination set–up as a light source. After 
illumination, the supplemented phenol red free DMEM was replaced with 
supplemented DMEM with phenol red and the plates were re-incubated for 
24 h.  
For both in vitro dark cytotoxicity and PDT activity, each experiment was 
performed in triplicate replicate and surviving cells were quantified after re–
incubation using WST-1 viability assay  
 
2.6.3. Cell viability determination 
The WST–1 assay was used to assess the toxicity and cell proliferation in the 
monolayer of the cells treated with the drugs and the control, respectively. 
This was performed as specified in the manufacturer’s instruction and a 
Synergy 2 multi–mode microplate reader (BioTek) set at a wavelength of 450 
nm was used to quantify the stained viable cells. The percent cell viability was 
determined using equation 2.1:   
       % cell viability =  Absorbance sample  
Absorbance control ×  100                                     (2.1)  
where the absorbance of sample is for cells containing drugs while absorbance 
of control is for control cells containing only supplemented DMEM with phenol 
red. 
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2.6.4 Statistical analysis  
The data obtained from the experiments was statistically analysed. Each 
sample was run 3 times and each experiment was repeated three times. One–
way analysis of variance (ANOVA) for the in vitro dark cytotoxicity and PDT 
data of the drugs against MCF-7 cell was evaluated. A p–value < 0.05 was 
considered to be statistically significant. 
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CHAPTER 3 
3. Synthesis and characterizaton 
This chapter gives details of the synthesis and the characterization of the 
MPcs, nanoparticles (NPs) and the MPc-NPs conjugates used in this work.  
 
3.1. Metalophthalocyanines (MPcs-complexes). 
The syntheses of complexes 1, 3a, 3b and 4a have been previously reported 
[37–40] thus their characterisation will not be discussed in this work. The 
characterization of new complexes 2, 4b and 5–8 will be discussed in detail 
in the following subsections. The synthesis of a new phthalonitrile, 4-[3-(4-
phenoxy)-propanoic acid] phthalonitrile which was used for the synthesis of 
complexes 2, 5, 6 and 7 will also be discussed.  
 
3.1.1. 4-[3-(4-phenoxy)-propanoic acid] phthalonitrile. 
The formation of 4-[3-(4-phenoxy)propanoic acid] phthalonitrile was via a 
nucleophilic substitution reaction of the hydroxyl moiety of the 3-(4-
hydroxyphenyl) propionic acid and the nitro group of the 4-
nitrophthalonitrile, Scheme 3.1.  
 
NC
NC
NO2 HO O OH O ONC
NC
OH
DMF, N2,
K2CO3, 36 h, rt
+
 
Scheme 3.1: Synthetic route for 4-[3-(4-phenoxy)propanoic acid] 
phthalonitrile. 
 
71 
 
The compound was characterised using FT–IR, 1H NMR and elemental 
analyses. The FT-IR spectrum of the substituted phthalonitrile (Figure 3.1) 
showed the presence of C≡N (2230 cm−1) and Ar-O-Ar (1228 cm−1) which is 
typical of ether substituted phthalonitrile. The presence of a carboxylic acid 
OH group (3300 cm−1) and C=O (1688 cm−1) show the successful substitution 
of 4-nitrophthalonitrile with 3-(4-hydroxyphenyl) propionic acid. 
The 1H NMR showed the aromatic protons between 7.89 - 7.12 ppm, the 
COOH proton was observed at 3.48 ppm and the CH2 groups of the propanoic 
acid chain at 2.85 ppm and 2.55 ppm. Peak integration gave the anticipated 
number of protons, confirming the purity of the phthalonitrile. The elemental 
analysis agreed with the proposed structure.  
 
3.1.2. Zinc(II) tetra–[3-(4-phenoxy)propanoic acid] phthalocyanine (2) 
and zinc(II) mono–[3-(4-phenoxy)propanoic acid] phthalocyanine (5). 
The synthesis of complex 2 was achieved by cyclocondensation of 4-[3-(4-
phenoxy)propanoic acid] phthalonitrile in the presence of a catalytic amount 
of DBU, Zn salt, and 1-pentanol. Complex 5 was formed by cross–
condensation of 1,2-dicyanobenzene and 4-[3-(4-phenoxy)propanoic acid] 
phthalonitrile in the presence of DBU, Zn salt, and 1-pentanol (Scheme 3.2). 
The disappearance of a dinitrile peak at 2230 cm−1 in the FT-IR spectrum of 
2 and 5 (Figure 3.1, using complex 2 as an example) confirmed the formation 
of the complexes.  
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Scheme 3.2: Synthetic routes for complexes 2 and 5. 
 
 
The 1H NMR spectra for complexes 2 and 5, showed aromatic ring proton 
peaks between 8.89−7.04 ppm, the COOH protons between 4.02 – 3.27 ppm 
and the CH2 groups of the propanoic acid chain were observed between 3.07 
– 2.67 ppm. Peak integration gave the anticipated number of protons for both 
complexes, confirming their purity.  
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Figure 3.1: FT-IR spectra for 4-[3-(4-phenoxy)propanoic acid] phthalonitrile 
(a) and complex 2 (b). 
 
The mass spectrum of 2 showed the molecular ion peak at m/z: 1234.23 [M]+, 
while that of 5 was found at m/z: 743.19 [M+H]+  and these agreed with the 
proposed structure in Schemes 3.2. The obtained elemental analyses agreed 
with the calculated inferring the purity of the complexes. 
The ground state absorption spectra for complexes 2 and 5 (Figure 3.2) 
showed monomeric behaviour of the complexes as evidenced by a single 
narrow Q band at 680 nm and 675 nm respectively (Table 3.1), as typically 
observed for metalated phthalocyanines with degenerate D4h symmetry [188]. 
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Figure 3.2: The ground state absorption spectra for complexes 2 and 5 in 
DMSO (insert: absorption spectra in water containing 1.6% DMSO). 
 
The red shift in the Q band of complex 2 compared to 5, can be attributed to 
a relative destabilization of the highest occupied molecular orbital (HOMO) 
due to the electron donating ability of the four phenoxy propionic acid groups 
in complex 2, compared to one phenoxy propionic acid group in complex 5. 
This in turn decreases the energy gap between the HOMO and lowest 
unoccupied molecular orbital (LUMO) of complex 2 [189].  
In water containing 1.6% DMSO (Figure 3.2, insert), the Q-bands are broad 
due to aggregation, typical of Pcs in aqueous solution due to π–π stacking 
interaction of the aromatic rings of Pcs [190]. The effect of aggregation is 
usually reduced by solubilization of the drug in a biocompatible surfactant 
for therapeutic formulations. Complexes and some conjugates are not soluble 
in water, hence 1.6% (v/v) DMSO in water was used for cell studies hence the 
importance of determining the parameters in its presence.  
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3.1.3. Indium(III) chloride tetra-(thiophine ethoxy) phthalocyanine (4b). 
Complex 4b was synthesised through a cyclocondensation reaction of 4-[2-(2-
thienyl)ethoxy] phthalonitrile in the presence of DBU and 1-pentanol to form 
an H2Pc. This was followed by metallation of the H2Pc using an indium salt to 
form complex 4b, Scheme 3.3.  
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Scheme 3.3:. Synthetic route for complex 4b. 
 
The disappearance of the C≡N peak of the phthalonitrile at 2228 cm−1 (Figure 
not shown) observed in the FT-IR spectra for complex 4b confirmed successful 
formation of a Pc. The 1H NMR spectrum for the H2Pc (Figure 3.3) displayed  
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aromatic ring proton peaks between 8.95−8.54 ppm and 7.61 − 7.04 ppm. 
The protons of the CH2 of the ethoxy groups were observed at 4.72 ppm and 
3.59 ppm. The NH peaks were shown at 4.32 ppm. Upon metallation with 
indium chloride similar peaks were observed with the disappearance of the 
NH peaks (Figure 3.3) showing successful metallation. Due to the presence 
of isomers most aromatic signals overlap resulting in the broadening of 
signals, however peak integration gave the expected total number of protons, 
confirming the purity of the complex. Mass spectral data (H2Pc m/z: 1019.30 
[M]+ and complex 4b m/z: 1167.26 [M]+) and elemental analyses agreed with 
the proposed structure in Scheme 3.3. 
 
Figure 3.3: Mass spectra for H2Pc and complexes 4b. 
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The absorption spectra for complex 4b and the already reported Zn(II) 
counterpart (complex 4a) [40] in DMSO are overlayed in Figure 3.4. These 
complexes showed monomeric behaviour as evidenced by narrow, single Q 
bands at 682 and 695 nm, for complexes 4a and 4b, respectively (Table 3.1). 
The Q band of complex 4b is slightly red shifted compared to 4a. The red 
shifting is attributed to the non-planar effect of the indium(III) ion, with a 
relatively bigger atomic radius than the zinc(II) as the central metal ion in the Pc 
cavity, and this relatively destabilizes the HOMO as explained before 
[189,191,192]. In water (containing 1.6% DMSO), there is broadening of Q 
bands (Figure 3.4, insert) but not split as observed above.  
 
 
Figure 3.4: The ground state absorption spectra for complexes 4a and 4b in 
DMSO (and water containing 1.6% DMSO, insert). 
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3.1.4. Zinc(II) [tris-(4-(benzothiazol-2-yl)phenoxy)- 3-(4-
phenoxy)propanoic acid] phthalocyanine (6) and zinc(II) [tris-(3-(4-
phenoxy)propanoic acid)-4-(bezothiazol-2-yl) phenoxyl] phthalocyanine 
(7). 
 
Complexes 6 and 7 were synthesized by a statistical cross–condensation 
reaction of 4-[4-(benzothiazol-2-yl)phenoxy] phthalonitrile and 4-[3-(4-
phenoxy)propanoic acid] phthalonitrile (mole ratios 5:1 and 1:5 respectively) 
in the presence of DBU, Zn salt and 1-pentanol as illustrated in Scheme 3.4.  
 
Scheme 3.4: Synthetic route for complexes 6 and 7. 
 
The disappearance of the characteristic C≡N peak of the dinitriles at 2238 
cm−1 and 2230 cm−1 in the FT-IR spectrum for complexes 6 and 7 respectively 
confirmed the conversion of the phthalonitriles to phthalocyanines. 
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The 1H NMR spectrum for complex 6 displayed peaks due to aromatic ring 
protons at 8.82 – 6.70 ppm, the CH2 protons at 4.07 ppm and 3.02 ppm, and 
the proton due to the hydroxyl group of a carboxylic acid at 12.27 ppm.  
On the other hand, the 1H NMR spectrum for complex 7 exhibited aromatic 
ring proton peaks between 7.81−7.09 ppm, the CH2 protons of the propionic 
acid chain at 2.89 ppm and 2.65 ppm, and the protons due to the hydroxyl 
groups of the carboxylic acid moiety at 11.32 ppm. Peak integration for both 
complexes gave the expected number of protons, confirming the purity of the 
Pcs. The mass spectral data (Figure 3.5) for complex 6 gave m/z: 1416.74 [M-
H]+) and complex 7 gave m/z: 1295.40 [M]+, and elemental analyses agreed 
with the proposed structure in Scheme 3.4. 
 
 
Figure 3.5: The MS (Maldi-TOF) for complexes 6 (and 7 insert). 
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An overlay of the normalized absorption spectra of complexes 6 and 7, is 
shown in Figure 3.6.  
 
 
Figure 3.6: The ground state absorption spectra for complexes 6 and 7 in 
DMSO (and water with 1.6% DMSO; insert). 
 
 
 
The complexes displayed a single Q band at 680 nm and 681 nm in DMSO, 
(Table 3.1). There is insignificant difference between the absorption spectra 
of the two complexes except that complex 6 with three benzothiazole groups 
showed intense absorption in the B-band region. This is probably because 
benzothiazole groups absorb within the same region. In water with 1.6% 
DMSO (Figure 3.6 insert), the Q-bands are broad due to aggregation, typical 
of Pcs in aqueous solution due to π–π stacking interaction of the aromatic 
rings of Pcs as explained above. 
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3.1.5. Zinc(II) [(tris- (2,2,7,7-tetramethyltetrahydro-3aH-bis([1,3] 
dioxolo)[4,5-b:4',5'-d]pyran-5-yl)methoxy)-2-(4-benzothiazol-2-yl)phenoxy] 
phthalocyanine (8)  
Complex 8 was synthesized through cross–condensation of a 4-glycosylated 
phthalonitrile and 4-[4-(benzothiazol-2-yl)phenoxy] phthalonitrile in the 
presence of DBU, zinc acetate, and 1-pentanol in an inert nitrogen 
atmosphere, Scheme 3.5.  
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Scheme 3.5: Synthetic route for complex 8. 
 
The disappearance of a phthalonitrile C≡N peak at 2234 cm−1 in the FT-IR 
spectrum for 8 confirmed the formation of the MPc. The 1H NMR spectrum 
displayed aromatic ring proton signals between 8.13 – 7.16 ppm.  
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The propyledene sugar ring protons were observed between 5.50 – 4.09 ppm, 
while the CH3 protons on the sugar were observed between 1.44 – 1.29 ppm. 
Signal integration gave the anticipated number of protons, confirming the 
purity of the complex. Mass spectral data (m/z: 1578.44 [M+H]+) and 
elemental analyses agreed with the proposed structure for complex 8. 
The complex displayed a single Q band at 681 nm in DMSO, however in water 
with 1.6% DMSO there was broadening of the Q band due to aggregation as 
previously mentioned. 
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Table 3.1: Q-band absorbance of complexes and their conjugates in DMSO  
Pc Q band (nm)a 
Complex 1 691 (708) 
1-Ag1Au3NSs-GSH 687 (704) 
1-Ag3Au1NSs-GSH 689 (705) 
1-Ag3Au1SiNSs- APTES 691 (702) 
Complex 2 680 (689) 
2-AuNTs-GSH 680 (687) 
2-AuNSs-GSH 679 (685) 
2-AgNSs -GSH 680 (686) 
2-Ag3Au1NSs-GSH 678 (694) 
Complex 3a 679 (688) 
3a-AuNTs-CTAC 679 (684) 
3a-AuNSs-CTAB  680 (685) 
3a-GSS 680 (687) 
Complex 3b 690 (705) 
3b-AuNTs-CTAC 693 (687) 
3b-AuNSs-CTAB  692 (686) 
3b-GSS 693 (701) 
Complex 4a 682 (695) 
4a-AuNTs-CTAC 681 (684) 
4a-AuNSs-CTAB  682 (685) 
4a-GSS 681(694) 
Complex 4b 695 (712) 
4b-AuNTs-CTAC 694 (707) 
4b-AuNSs-CTAB  695 (701) 
4b-GSS 697 (711) 
Complex 5 675 (686) 
5-AuNTs-GSH 673 (685) 
5-AuNSs-GSH 674 (684) 
5-AgNSs -GSH 674 (683) 
5-Ag3Au1NSs-GSH 673 (684) 
Complex 6 680 (687) 
6-AuNTs-GSH 681 (685) 
6-AuNSs-GSH 679 (684) 
6-AuNTs-CTAC  680 (689) 
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6-AuNSs-CTAB  680 (687) 
b 6-AuCT 679 (681)  
b6-CT 681 (683)  
Complex 7 681(687) 
7-AuNTs-GSH 680 (686) 
7-AuNSs-GSH 681(685) 
7-AuNTs-CTAC  681 (682) 
Complex 8 681 (684) 
8-AuNSs-CTAB  681 (684) 
8-AuNRs-CTAB 682 (684) 
 
anumbers in brackets are the values in water (with 1.6% DMSO). CTAB and 
CTAC left on the conjugate names to show the starting capping agent on the 
NPs. 
bvalues obtained in 1% acetic acid in DMSO or water (with 1.6% DMSO). 
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3.2. Nanoparticles and composites 
This section outlines the synthesis and the characterization of the 
nanoparticles (NPs) and composites  
 
3.2.1. Gold and silver nanoparticles  
The syntheses of GSH capped AgNSs-GSH [179], AuNSs-GSH [180], as well 
as the CTAB capped AuNSs-CTAB, AuNRs-CTAB [181] and CTAC capped 
AuNTs-CTAC [182] have been reported before. Ag3Au1NSs-GSH, 
Ag1Au3NSs-GSH [122], GSS [183,184] and AuCT [186,187] are also known 
but were synthesised with modification. The synthesis and characteisation 
of Ag1Au3NSs-APTES and AuNTs-GSH are reported for the first time. 
The alloy nanoparticles Ag1Au3NSs-OA/OLA and Ag3Au1NSs-OA/OLA were 
synthesised using oleic acid and oleylamine as surfactants, solvents, 
reducing and stabilizing agents. This method was chosen specifically for 
alloys since the amine group in oleylamine can co-reduce both gold and 
silver ions to produce nanoalloys at high temperature [193,194]. The 
weakly bound OA/OLA on the nanoparticles are readily displaced with 
either glutathione or APTES. 
AuNRs, AuNSs and AuNTs were synthesised using the seed growth method, 
using CTAB as a capping agent for AuNRs and AuNSs, and CTAC for AuNTs. 
The capping agent that produced a high yield based on literature was 
chosen [181,182]. For the GSH functionalised NPs, the weakly absorbed 
86 
 
capping agent on the nanoparticles are readily displaced with GSH. 
The absorption spectra of the spherical silver (AgNSs-GSH) and gold 
(AuNSs-CTAB/ AuNSs-GSH) nanoparticles showed their characteristic 
surface plasmon resonance (SPR) peaks at 420 nm and 525/532 nm 
respectively (spectra not shown). The normalised absorption spectra of 
AuNTs-CTAC and AuNRs-CTAB are shown in Figure. 3.7.  
For AuNTs-CTAC, an intense band (dipole) around 638 nm and a weak 
shoulder (quadrupole) around 528 nm are observed, and these are 
attributed to the in-plane dipole and out-of-plane dipole resonance of gold 
nanoplates, respectively, which are characteristic bands of AuNTs 
[195,196], Figure. 3.7A. The absorption spectrum for AuNTs-GSH (not 
shown) was similar to that of AuNTs-CTAC with the dipole peak at 607 nm  
and the quadrupole peak around 532 nm. The differences in the positions 
of the dipole peaks for AuNTs-ATAC and AuNTs-GSH could be due to the 
differences in the sizes of NTs (AuNTs-CTAC 52.7/62.3 nm and AuNTs-
GSH, 33.2 nm edge length) as shown in Table 3.2. 
The insert in Figure. 3.7A shows the TEM micrographs of the AuNTs-CTAC 
as a representative for AuNTs-GSH. The image shows different sizes of 
nanotriangles, which could be responsible for the dipole peak at 638 nm 
(for larger size) and a shoulder peak at 600 nm (for smaller size) in the 
absorption spectrum of AuNTs- CTAC, Figure 3.7A. In addition to AuNTs, 
the TEM image also shows a few irregular nanoparticles, hexagons and 
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spheres, which could be responsible for the quadrupole peak in the 
absorption spectrum [196].  
 
 
 
Figure 3.7: The normalized absorption spectrum for AuNTs-CTAC and 
AuNRs-CTAB (insert shows TEM images of NPs). 
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On the other hand, AuNRs–CTAB (Figure. 3.7B) displayed two SPR bands 
at 519 nm and 662 nm, due to their anisotropic shape (as shown by the 
TEM micrograph in Figure. 3.7B, insert) corresponding to their width and 
length known as the transverse mode and longitudinal mode, respectively 
[197].  
X-ray diffractometry was used to give structural information of NPs and 
their conjugates with relation to the broadness or sharpness of the XRD 
peaks, which is indicative of their amorphous or crystalline nature. The 
powder XRD pattern for AuNSs-CTAB is shown in Figure 3.8, as a 
representative of other AuNPs (AuNSs-GSH, AuNRs-CTAB, AuNTs-GSH and 
AuNTs-CTAC). The XRD displayed peaks around 2θ = 38.4°, 44.7°, 64.9°, 
77.6° and 81°, showing crystallinity (matching the pattern in card number, 03-
065-2870; NIST:N AL3280 from the powder diffraction database). These peaks 
were assigned to the 111, 200, 220, 311 and 222 planes respectively, 
corresponding to the face centered cubic crystal (FCC) structure of metallic 
gold [198,199]. 
 
Size estimates from XRD were obtained only for some NPs using the Debye–
Scherrer [200] as shown in equation 3.1, by focusing on the peaks at plane 111: 
                   d = 𝑘𝑘λ
βcosθ
     (3.1) 
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where λ is the wavelength of the X-ray source (1.5405 Å), k is an empirical 
constant equal to 0.9, β is the full width at half maximum of the diffraction 
peak and θ is the angular position. The size estimates are shown in Table 3.2 
and will be discussed later. 
 
Figure 3.8: XRD patterns for AuNSs-CTAB, Ag3Au1SiNSs–APTES, AuCT, 
GSS, 6-AuNSs-CTAB and complex 6 as representatives. 
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Table 3.2: Sizes and loading of conjugates. 
Sample Sizea (nm) Loading (μg/mg) 
Complex 1   
1-Ag1Au3NSs-GSH 21.1 (18.9) XRD c 
1-Ag3Au1NSs-GSH 17.5 (15.1) XRD c 
1-Ag3Au1SiNSs- APTES  b(73) 19 
Complex 2   
2-AuNTs-GSH 34.9 (33.2)  22 
2-AuNSs-GSH 14.9 (13.6) 27 
2-AgNSs -GSH 14.7 (11.1) 9 
2-Ag3Au1NSs-GSH 17.3 (15.1) 41 
Complex 3a   
3a-AuNTs-CTAC 54.6 (52.7) 15 
3a-AuNSs-CTAB  16.4 (15.2)  22 
3a-GSS 88.1 (81.7) 50 
Complex 3b   
3b-AuNTs-CTAC 55.9 (52.7) 20 
3b-AuNSs-CTAB  16.9 (15.2)  32 
3b-GSS 86.4 (81.7) 48 
Complex 4a   
4a-AuNTs-CTAC 54.9 (52.7) 24 
4a-AuNSs-CTAB  17.2 (15.2)  37 
4a-GSS 81.7 (78.4) 51 
Complex 4b   
4b-AuNTs-CTAC b (52.7) 17 
4b-AuNSs-CTAB  16.7 (15.2)  29 
4b-GSS 82.3 (78.4) 49 
Complex 5   
5-AuNTs-GSH 36.9 (33.2) 16 
5-AuNSs-GSH 13.8 (13.6) 20 
5-AgNSs-GSH 12.2 (11.1) 10 
5-Ag3Au1NSs-GSH 16.5(15.1) 28 
Complex 6   
6-AuNTs-GSH 37.1 (33.2) 30 
6-AuNSs-GSH 19.8 (17.7) 37 
6-AuNTs-CTAC  66.8 (62.3)  42 
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6-AuNSs-CTAB  13.4 (11.7) DLS 37 
6-AuCT 357 (345) DLS 32 
6-CT 329 (324) DLS 28 
Complex 7   
7-AuNTs-GSH 35.3 (33.2)  26 
7-AuNSs-GSH 17.1 (14.9) 38 
7-AuNTs-CTAC  65.7 (62.3)  33 
Complex 8   
8-AuNSs-CTAB  15.28 (13.4) 8 
8-AuNRs-CTAB 3.2 (2.1) 14 
 
anumbers in brackets are the sizes of NPs alone and the sizes are from TEM 
unless otherwise stated. 
aThe the edge length was measured for all nanotriangles and diameters for 
the spheres. Aspect ratios were used for the nanorods. 
aNote: Size of the NPs of the same shape varies because they were prepared 
in different batches. 
bSizes not obtained due to extensive aggregation. 
cSample no longer available for the study and since both NP synthesis and 
loading are sensitive to conditions it will be difficult if not impossilbe to 
reproduce the conjugate with the same loading.  
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3.2.2. AgxAuy alloy nanoparticles.  
The alloy NPs Ag3Au1NSs-GSH, Ag1Au3NSs-GSH and Ag3Au1SiNSs-APTES 
were synthesised as illustrated in Scheme 3.6. The weakly bound OA/OLA 
on the nanoparticles were replaced by glutathione, Scheme 3.6A.  
For the synthesis of Ag3Au1SiNSs-APTES, silica was grown on Ag3Au1NSs 
surfaces using hydrolysis and condensation of tetraethyl orthosilicate 
(TEOS)  under basic conditions, allowing a slow, controlled growth of a shell 
around the alloys [183]. The silica shell was further functionalised through 
the  displacement of hydroxyl groups on the silica shell with the alkoxy 
groups on APTES thus forming a covalent -Si-O-Si- bond, Scheme 3.6B. 
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Scheme 3.6: Synthetic route for (A) Ag3Au1NSs-GSH, Ag1Au3NSs-GSH and 
(B) Ag3Au1SiNSs-APTES. 
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The surface plasmon resonance peaks of Ag3Au1NSs-GSH and Ag1Au3NSs-
GSH were observed at 410 nm and 506 nm in DMSO, respectively (Figure 
3.9). The SPR peaks of these alloys are very close to the SPR positions of 
individual AgNSs and AuNSs, depending on the composition of Ag or Au 
present in the alloys [201].  
 
Figure 3.9: The normalized absorption spectrum for Ag1Au3NSs-GSH (a) 
Ag3Au1NSs-GSH (b) and Ag3Au1SiNSs- APTES (c) (insert shows TEM image of 
Ag3Au1SiNSs- APTES). 
 
No significant absorption peak was observed for Ag3Au1NSs in Ag3Au1SiNSs-
APTES (Figure 3.9c) which could be attributed to successful doping of the 
NPs into SiNSs. Hence the Ag3Au1NSs are not exposed and do not show the 
SPR band. This confirms that the Ag3Au1NSs are embedded within the SiNSs. 
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The TEM image of the Ag3Au1SiNSs–APTES, Figure 3.9 insert, shows a dark 
core with a light ring around it (shell), an indication that silica has formed a 
coat on the Ag3Au1NSs surface. 
 
The powder XRD pattern for Ag3Au1SiNSs–APTES is shown in Figure 3.8, and 
it is a representative for Ag3Au1NSs-GSH and Ag1Au3NSs-GSH. The pattern 
corresponds to the FCC structure of metallic gold as previously explained. 
However it should be noted that gold and silver have the same pattern 
[198,199], (which matches the pattern in card number, 01-071-9134; ICSD 
104385 from the powder diffraction database). 
 
It is important to note that XRD pattern is observed for Ag3Au1 within 
Ag3Au1SiNSs–APTES while the SPR band was not observed in the absorption 
spectrum (Figure 3.9c) due to the penetrating nature of the XRD. The 
diffraction pattern does confirm the presence of Ag3Au1 within the SiNSs. 
 
3.2.3. Gold speckled silica (GSS) nanoparticles. 
Gold-speckled silica (GSS) nanoparticles were synthesized using 3-
aminopropyl-triethoxysilane (APTES) functionalised silica nanospheres 
(SiNSs-APTES) [183,184] and gold nanoparticles seeds [185] as explained in 
literature, Scheme 3.7. 
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Scheme 3.7. Synthetic route of GSS (rt = room temperature). 
 
GSS displayed a maximum absorption band at 599 nm (Figure 3.10) which 
is attributed to the surface plasmon resonance (SPR) peak of the nanogold on 
silica surfaces which is more red-shifted compared to the reported values [93] 
for GSS, probably due to the larger size of GSS. 
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Figure 3.10: The normalized absorption spectrum for GSS (insert shows TEM 
images of NPs). 
 
The TEM micrograph for GSS, Figure 3. 10 (insert), shows discontinuous and 
random deposits of nanogold (as shown by small darker spheres) on silica 
surfaces, confirming the formation of gold speckled SiNSs (GSS). 
 
The powder XRD pattern for GSS is shown in Figure 3.8. The pattern 
corresponds to the FCC structure of metallic gold as previously explained, 
however a broad peak was observed at 2θ = 10° to 22°, and it was attributed to 
the amorphous nature of SiNSs in GSS. 
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3.2.4. Chitosan and gold chitosan composite.  
The AuCT composite was synthesised using a CT solution and AuNSs as 
illustrated in Scheme 3.8. 
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Scheme 3.8: Synthetic route for AuCT and 6-AuCT. 
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CT alone (Figure 3.11), showed minimal absorption between 500 nm and 800 
nm. After linkage with AuNPs to form AuCT, an SPR peak was observed at 
548 nm, signifying the presence AuNPs in chitosan, Figure 3.11. The reduced 
intensity of the Au SPR peak could be an indication that some of the Au is 
embedded inside the biopolymer. 
 
 
Figure 3.11: The normalized absorption spectrum for CT and AuCT (insert 
shows TEM images of AuCT composite). 
 
The powder XRD pattern for AuCT corresponds to the FCC structure of metallic 
gold as previously explained (Figure 3.8) and slight boadening was observed 
between 2θ = 10° to 22°, probably due to the amorphous nature of CT. 
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Dynamic light scattering (DLS) is a light scattering technique used to 
determine the size-distribution profile of molecules (emulsions, micelles, 
polymers or nanoparticles) in solution. DLS was used to determine the size of 
CT, AuCT and their conjugates to complex 6, Figure 3.12 and the size 
estimates are shown in Table3.2. The sizes will be discussed below (section 
3.3.3). 
 
 
Figure 3.12. Dynamic light scattering curves for CT (A), 6-CT (B), AuCT (C) 
and 6-AuCT (D) in 1% (v/v) aqueous acetic acid solution (containing 1.6% 
(v/v) DMSO for 6-CT and 6-AuCT). 
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3.3. Metallophthalocyanines–nanoparticles conjugates. 
MPcs were linked to NPs through either an amide bond formed between the -
COOH group of the MPcs and the -NH2 of the GSH or APTES functionalised 
NPs or directly through self-assembly, taking advantage of the affinity of gold 
within the NPs for S or N in the complexes.  
 
3.3.1. Conjugates to GSH or APTES functionalised NPs (amide bond).  
Complexes 1, 2, and 5-7, all with a -COOH group (Table 1.1), were covalently 
linked to glutathione functionalised NPs (and 3-aminopropyl-triethoxysilane 
functionalized NPs for complex 1) via an amide bond. Scheme 3.9 shows the 
covalent linkage of complex 1 to Ag3Au1SiNSs-APTES and Ag1Au3NSs-GSH (as 
examples). 
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Scheme 3.9: Synthetic route for 1-Ag3Au1SiNSs-APTES and 1-Ag1Au3NSs-
GSH (DCC= N,N’-dicyclohexylcarbodiimide; DMAP= 4-
(dimethylamino)pyridine; rt= room temperature) 
 
The FTIR spectra (Figure. 3.13, using AuNTs-GSH, 2-AuNTs-GSH and 
complex 2, as examples) were employed to prove amide bond formation 
between the Pc complexes and the NPs.  
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Figure 3.13: FTIR spectra of AuNTs-GSH, 2-AuNTs-GSH and complex 2. 
 
The FTIR spectrum of AuNTs-GSH exhibited characteristic primary amide 
double peaks at 1529 cm-1 and 1585 cm-1 and also at 3260 cm-1  and 3313 
cm-1 which changed to single (secondary amide) peaks at 1540 cm-1 and 3248 
cm-1, respectively on linkage of AuNTs-GSH to complex 2, confirming the 
formation of an amide bond between glutathione functionalized NPs and the 
Pc complex. Also observed was the disappearance of 1706 cm−1 and 1603 cm-
1 peaks in complex 2 and 1629 cm-1 in AuNTs-GSH. Shifts and changes in 
the IR bands confirm structural change [202]. An amide peak was observed 
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at 1655 cm-1 after conjugation; however, it should be noted that GSH alone 
has amide bonds shown by peaks at 1654 cm−1 and 1629 cm−1 in AuNTs-GSH. 
The same trend was observed for the conjugates: 1-Ag1Au3NSs-GSH, 1-
Ag3Au1NSs-GSH, 1-Ag3Au1SiNSs-APTES, 2-AuNSs-GSH, 2-AgNSs-GSH, 2-
Ag3Au1NSs-GSH, 5-AuNTs-GSH, 5-AuNSs-GSH, 5-AgNSs-GSH, 5-
Ag3Au1NSs-GSH, 6-AuNTs-GSH, 6-AuNSs-GSH, 7-AuNTs-GSH and 7-
AuNSs-GSH. 
Figure 3.14A and B, shows the normalized absorption spectra for the 
conjugates of complexes 1 and 2 respectively, to glutathione functionalised 
NPs as examples. Slight blue shifts in the Q band of the conjugates (except 
for 1-Ag3Au1SiNSs-APTES in DMSO) when compared to complex 1 alone were 
observed in both DMSO and water with 1.6% DMSO (Table 3.1). The slight 
blue shifts could be attributed to the electron deficiency induced on the Pcs 
upon coordination with NPs as reported before [203]. However, for complexes 
2 and 5-8, insignificant or no shifts in the Q-bands were observed (Table 3.1). 
Phthalocyanines do not display any significant absorbance between the Soret 
band and the Q band; however on conjugation to gold NPs or silver NPs or 
gold-silver alloy NPs, all conjugates except 1-Ag3Au1SiNSs-APTES, displayed 
increased absorption between the Soret and the Q band (Figure 3.14A,B)  
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Figure 3.14: The normalized absorption spectra for (A) complex 1, 1-
Ag1Au3NSs-GSH, 1-Ag3Au1NSs-GSH and 1-Ag3Au1SiNSs-APTES; (B) complex 
2, 2-AuNTs-GSH, 2-AuNSs-GSH, 2-AgNSs-GSH and 2-Ag3Au1NSs-GSH. 
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corresponding to the SPR band for the respective NPs, confirming the 
conjugation of NPs to complexes. The same enhancements were also observed 
for the conjugates in water with 1.6% DMSO (spectra not shown). The 
spectrum of 1-Ag3Au1SiNSs-APTES both in DMSO (Figure 3.14A) or water 
with 1.6% DMSO (spectrum not shown) did not show these SPR bands as also 
observed for Ag3Au1SiNSs-APTES alone. Since complex 1 is linked to the 
surface of the SiNSs in 1-Ag3Au1SiNSs-APTES, its spectrum is observed unlike 
for Ag3Au1SiNSs-APTES where the AuNSs and AgNSs are embedded within 
SiNSs, hence the SPR band is not observed. 
 
The TEM micrographs of the conjugates (Figure 3.15, using 2-AuNSs-GSS 
and 6-AuNTs-GSH as representatives) generally displayed aggregation, 
possibly due to - stacking between the Pcs on adjacent nanoparticles. Pcs 
are known for their - stacking to form H aggregates [190]. 
 
 
Figure 3.15: TEM images for 2-AuNSs-GSH and 6-AuNTs-GSH. 
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3.3.2. Au-S or Au-N self-assembly conjugates.  
Complexes 3a, 3b, 6, 7 and 8, with a thiazole group together with 4a and 
4b, with a thiophine group (Table 1.1), were linked to gold containing NPs 
(either AuNTs-CTAC or AuNSs-CTAB or AuNRs-CTAB or GSS or AuCT) via Au-
S or Au-N interaction (the latter for the complexes with both N and S). Scheme 
3.10 shows the Au-S/Au-N interaction of complex 8 with AuNSs-CTAB, as a 
representative. The Au-S/Au-N interaction is also represented in Scheme 3.8, 
using 6-AuCT. 
 
 
Scheme 3.10: Synthetic route for 8-AuNSs-CTAB (rt = room 
temperature) 
The capping agents CTAB and CTAC are loosely bound on the AuNPs, 
however on conjugation some of the capping agents are replaced by MPc 
complexes to form Au-S or Au-N bonds. 
Upon conjugation of complexes 3a, 3b, 4a, 4b, 6, 7 to AuNSs-CTAB and 
AuNTs-CTAC, and complex 8 to AuNSs-CTAB and AuNRs-CTAB, an 
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enhancement in absorption between the Q band and 500 nm was observed 
(Figure. 3.16, using the normalized absorption spectra of 8, 8-AuNSs-
CTAB and 8-AuNRs-CTAB as representatives), confirming successful 
linkage of the complexes to nanoparticles.  
 
Figure. 3.16. The normalized absorption spectra for 8, 8-AuNSs-CTAB 
and 8-AuNRs-CTAB in DMSO (and in water with 1.6% DMSO as shown 
by the insert). 
 
Table 3.1 shows insignificant shifts in the Q-band absorbance of Pc 
complexes 3a, 3b, 4a, 4b and 6-8 in DMSO on conjugation. In water (with 
1.6% DMSO), there is aggregation as discussed above (Figure. 3.16 
insert)  
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To confirm interaction between the gold containing NPs (AuNTs-CTAC, 
AuNSs-CTAB, AuNRs-CTAB, GSS and AuCT) and Pc complexes, XPS 
analysis was done. Figure. 3.17 shows high resolution XPS spectra for 
complex 6 S2p, complex 6 N1s, 6-AuCT S2p and AuCT N1s as representatives 
for other complexes and conjugates.  
The S2p deconvolution for complex 6 alone (Figure 3.17A) exhibited two 
sub-peaks corresponding to –S–C– (161.9 eV) and –S– (163.0 eV) and similarly 
the N1s of the complex alone (Figure 3.17B) exhibited two sub-peaks 
corresponding to –N–C– (396.1 eV) and –N– (397.9 eV). The N1s peak for 
AuCT (Figure 3.17D) displayed three peaks attributed to –N–C– 
(397.8eV), –N– (399.7eV) and –N–Au– (400.7 eV). The nitrogen to gold 
interaction (–N–Au–) confirms successful linkage of CT to Au in AuCT Figure 
3.17D.  
The gold containing conjugate displayed three peaks (Figure 3.17C) 
attributed to –S–C– (162.3 eV), –S– (163.7 eV) and –S–Au– (164.9 eV). The 
sulphur to gold interaction (–S–Au–) confirms successful linkage of complex 6 
to AuCT to form 6-AuCT. Since complex 6 contains both S and N, a nitrogen 
to gold interaction (N-Au) was also expected, however this was not observed 
in the XPS spectra for 6-AuCT.  
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Figure. 3.17: High resolution XPS spectra for (A) complex 6 (S 2p), 
complex 6 (N1s), 6-AuCT (S 2p) and AuCT (N 1s). 
 
 
Figure. 3.18: High resolution XPS spectra for (A) complex 8 (N1s), 8-
AuNSs-CTAB (N 1s). 
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Figure. 3.18 shows high resolution XPS spectra for complex 8 N1s and 3–
AuNSs-CTAB N1s as representatives for conjugates with Au-N and Au-S 
interactions. The N1s peak for complex 8 alone (Figure 3.18A) showed two 
subpeaks corresponding to –N–C– (396.2eV) and –N– (397.3eV), while the 
conjugate (Figure 3.18B,) displayed three peaks attributed to –N–C– 
(396.3eV), –N– (397.3eV) and –N–Au– (399.9 eV), confirming a Au-N bond. 
It should be noted that some conjugates (7-AuNTs-CTAC, 8-AuNSs-CTAB and 
8-AuNRs-CTAB) displayed the presence of both the gold to sulfur and gold to 
nitrogen interactions (–N–Au– and –S–Au–) suggesting that both S and N on 
the same Pc molecule are linked to AuNPs or that some molecules were 
adsorbed on the surface of metallic nanoparticles through S-Au interactions 
while others utilized the N-Au interactions since gold has a strong affinity for 
both sulphur and nitrogen.  
The X-ray diffraction pattern of all the conjugates (except 6-CT) was similar 
to that of the NPs, with a characteristic powder diffraction pattern of gold and 
silver (Figure 3.8, using 6-AuNSs-CTAB as a representative for conjugates) 
as explained before due the presence of the NPs with gold or silver in the 
conjugates. Broad peaks between 2θ = 15–23°, were observed for Pc complexes 
alone (Figure 3.8, using complex 6 as a representatives for Pcs), typical of the 
amorphous nature of phthalocyanines [204] and these were also observed in 
all conjugates, providing evidence for the presence of the phthalocyanines in 
the conjugates. 
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The TEM micrographs of the conjugates (Figure 3.19, using 4b-GSS and 7-
AuNTs-CTAC as representative) generally displayed extensive aggregation 
when compared to NPs alone (Figure 3.7 insert and Figure 3.10 insert). 
Aggregation is possibly due to - stacking between the Pcs on adjacent 
nanoparticles as previously stated.  
 
Figure. 3.19: TEM images of 4b-GSS and 7-AuNTs-CTAC. 
 
 
3.3.3. Sizes of NPs and conjugates 
The sizes of NPs and their conjugates are as shown in Table 3.2. It should be 
noted that the average size of the NPs of the same shape varies because they 
were prepared in different batches. The size (and shape) of NPs is greatly 
affected by many factors including temperature, volume and pH of the 
solution, pressure, time, synthesis method used, surfactant amount used, 
exposure to light, concentration of starting material and the stirring rate 
during synthesis [205–209], hence it is expected that different batches will 
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differ in size since it difficult to follow the exact steps of the previous protocol 
due to variations (however slight) in the above stated conditions.  
As shown in Table 3.2, the sizes of the GSH functionalised alloy NPs are 18.9 
nm and 15.1 nm for Ag1Au3NSs-GSH and Ag3Au1NSs-GSH respectively. The 
differences in size could be due to differences in the concentration of the gold 
and silver salt used, in addition to slight differences in the synthesis protocol 
as explained above. 
The large size for the Ag3Au1SiNSs-APTES (73 nm) shows that the SiNSs 
formed a coat on aggregates of Ag3Au1NSs-OA/OLA forming large particles. 
This is confirmed by the TEM image in Figure 3.9 (insert), showing a dark 
core with a light ring around it. 
The synthesis protocol of AuNTs is very sensitive to temperature, hence the 
differences in sizes for AuNTs-CTAC (52.7nm and 62.3 nm edge length) are 
probably due to fluctuations in the room temperature in addition to other 
conditions as previously explained. The same applies to AuNSs-GSH (13.6 
nm, 14.9 nm or 17.7 nm in diameter) and AuNSs-CTAB (11.7, 13.4 nm or 
15.2 nm diameter). Only one size was used for AuNTs-GSH (33.2 nm edge 
length) and AgNSs-GSH (11.1 nm) since these were prepared in one batch. 
The large size for the GSS is due to the large SiNSs used as shown by the TEM 
image in Figure 3.10 (insert), showing the large SiNSs in grey and small 
speckles of gold in black. CT is a biopolymer hence it is large as shown by the 
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DLS size (and the white spheres in Figure 3.11, insert), however it should be 
noted that DLS gives the hydrodynamic diameter hence the sizes are always 
larger. Generally, all sizes increased following conjugation. 
 
3.3.4. Loading of MPcs to NPs. 
The size of an MPc is ~1 nm while that of NPs is usually greater 1 nm. Thus, 
more than one Pc can bind to NPs, and this is termed loading. The loading of 
complexes onto the nanoparticles was investigated following literature 
methods [210]. Briefly this involved comparing the Q band absorbance 
intensity of the MPc in the conjugate with that of the MPc before conjugation. 
The representative loading values are shown in Table 3.2.  
Less loading of MPcs on the AuNTs-CTAC (52.7 nm and 62.3 nm edge lengths) 
was observed for MPc–AuNTs-CTAC conjugates, unlike AuNSs-CTAB (11.7, 
13.4 nm or 15.2 nm diameter) which afforded more loading of MPcs on their 
surface compared to the former, Table 3.2. The same applies to AuNTs-GSH 
(33.2 nm edge length) compared AuNSs-GSH (13.6 nm, 14.9 nm or 17.7 nm 
in diameter). This could be due to the plate like nature of these nanotriangles 
(also termed nanoplates) that tends to stack on each other face-to-face or edge 
to edge [211] in addition to the larger size as shown by the longer edge length. 
This reduces the loading capacity of the nanoparticles. The loading capacity is 
greatly influenced by the nanoparticle surface area [212], which in this case 
is greatly affected by the particle size and aggregation [213]. Size reduction 
increases the percentage of atoms at the surface [214], hence more loading.  
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Conjugates with GSS (78.4 nm and 81.7 nm diameter), displayed the highest 
loading probably due to the porous nature of silica in GSS which provides 
more surface area for loading than other NPs.  
Thus it can be inferred that the NPs having either small sizes or are porous 
generally displayed more loading of the Pcs onto their surfaces than those 
with bigger sizes due to the high surface area which allows for high loading 
[215].  
 
3.4. Summary of chapter  
The synthesis and characterizations of Pcs, NPs and the conjugates were 
presented in this chapter. The Pcs were characterized using 1H NMR, mass, 
UV-Vis, FTIR spectroscopies and elemental analysis to confirm the respective 
substituted Pcs. All the studied complexes 1-8 showed monomeric Q-band in 
DMSO, however in water (with 1.6% DMSO) there was broadening of the 
Q band due to aggregation. 
UV Vis, X-ray diffractometry, DLS (for CT and AuCT) and TEM were used for 
the characterisation of NPs. NPs were synthesised in different batches hence 
there are different sizes for the same shape NPs (AuNSs-CTAB, 11.7 (DLS), 
13.4 nm and 15.2 nm in diameter; AuNSs-GSH 13.6 nm, 14.9 nm and 17.7 
nm in diameter; AuNTs-CTAC, 52.7 nm and 62.3 nm in edge lengths; AuNTs-
GSH, 33.2 nm in edge length and GSS, 78.4 and 81.7 nm in diameter).  
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The X-ray diffraction pattern of all the conjugates (except 6-CT, which showed 
only broad amorphous peaks) was similar to that of the NPs, with a 
characteristic powder diffraction pattern of gold (or silver) showing the 
presence of gold or silver in the conjugates. The presence of the amorphous 
phthalocyanines in the conjugates was shown by broad peaks between 2θ = 
15–23°.  
FT–IR and X–ray photoelectron spectroscopic techniques were used to confirm 
the linkage of Pcs to NPs. FTIR confirmed successful formation of the amide 
bonds and XPS confirmed Au-S/Au-N interactions.  
The conjugates to AuNSs generally displayed high loading of the Pcs onto their 
surfaces than their AuNTs counter parts and this was attributed to the large 
surface area associated with small particle sizes which allows for high loading. 
Conjugates to GSS also displayed high loading due to the porous nature of 
SiNSs in GSS which increases the surface area for loading. 
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CHAPTER 4 
 
 
4. Photophysical and Photochemical Properties 
  
The chapter discusses the photophysical and photochemical behaviour; 
fluorescence quantum yields and life-times, triplet quantum yields and life-
times, and singlet oxygen quantum yields of phthalocyanines when alone and 
when conjugated to nanoparticles.  
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4.1. Fluorescence spectra, lifetimes and quantum yields  
4.1.1. Fluorescence excitation and emission spectra 
Figure 4.1 shows an overlay of the absorption, emission and excitation 
spectra of complex 7 and 7-AuNTs-CTAC in DMSO as representatives for 
other complexes and their conjugates. The ground state absorption and 
excitation spectra are mirror images of the emission spectrum. The closeness 
of the Q-band absorption and excitation maxima (Figure 4.1A) shows that 
the nuclear configurations of the ground and excited states are similar and 
are not affected by excitation in DMSO. It also shows that the complexes are 
not aggregated in DMSO. Similar fluorescence behaviour was observed for all 
Pc complexes alone. The slight differences between absorbance and excitation 
wavelengths for some complexes are due to the differences in equipment used, 
while the differences observed in the conjugates (Figure 4.1B) are attributed 
to the absorbance by the nanoparticles in the conjugate. 
 
Figure 4.1: Absorption (black), excitation (blue) and emission (red) spectra 
of complex 7 (A) and 7-AuNTs-CTAC (B) in DMSO as a solvent. 
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4.1.2. Fluorescence quantum yields (ΦF) and lifetimes (τF) 
The fluorescence quantum yields (ΦF) were determined by a comparative 
method [163,164] and calculated according to Equation 1.1, using 
unsubstituted ZnPc in DMSO (ΦF = 0.2) [46] as a standard. The fluorescence 
lifetimes (τF) were obtained using the time correlated single photon counting 
(TCSPC) method. Table 4.1 shows the ΦF and τF values of the complexes and 
their respective conjugates in DMSO. The ΦF values in water with 1.6% DMSO 
were <0.01 probably due to aggregation, thus were not shown in Table 4.1. 
The fluorescence decay curve for 4a-AuNTs-CTAC is shown as an example in 
Figure 4.2, and this is used as a representative for all the Pcs and their 
conjugates.  
 
Figure 4.2: Fluorescence decay (blue), χ2 fitting (red) and IRF (black) curves 
for 4a-AuNTs-CTAC in DMSO. 
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Table 4.1: Fluorescence quantum yield and lifetime parameters of the Pcs   
and the respective conjugates in DMSO. 
Sample ΦF (±0.01) τF(ns) (%) 
(±0.01) 
Mean 
τF (ns)  
𝛕𝛕𝟎𝟎 (ns) aSize of NPs 
alone (nm)  
Loading 
(μg/mg) 
Complex 1 0.02 2.43 (100) 2.43 121.5   
1-Ag1Au3NSs-GSH < 0.01 0.32 (51) 
3.26 (49) 
1.75 - 18.9 XRD c 
1-Ag3Au1NSs-GSH < 0.01 0.34 (78) 
3.27 (22) 
0.98 - 15.1 XRD c 
1-Ag3Au1SiNSs- 
APTES 
0.01 0.31 (81) 
5.15 (19) 
1.25 125.0 73 19 
Complex 2 0.19 3.36 (100) 3.36 17.7   
2-AuNTs-GSH 0.13 3.05 (100) 3.05 23.5 33.2  22 
2-AuNSs-GSH 0.03 2.88 (98) 
2.38 (2) 
2.87 95.7 13.6 27 
2-AgNSs -GSH 0.11 2.95 (100) 2.95 26.8 11.1 9 
2-Ag3Au1NSs-GSH 0.04 2.90 (96.8) 
1.96 (3.2) 
2.87 71.8 15.1 41 
Complex 3a 0.17 3.08 (100) 3.08 18.1   
3a-AuNTs-CTAC  0.16 2.90 (96.7) 
1.99 (3.3) 
2.87 17.9 52.7 15 
3a-AuNSs-CTAB  0.14 2.71 (89.1) 
1.98 (10.9) 
2.63 18.8 15.2 22 
3a-GSS 0.13 2.81 (97.6) 
1.98 (2.4) 
2.79 21.4 81.7 50 
Complex 3b 0.03 0.78 
(100) 
0.78 26.0   
3b-AuNTs-CTAC <0.01 0.66 (72) 
0.37 (28) 
0.58  - 52.7 20 
3b-AuNSs-CTAB  <0.01 0.58 (65) 
0.32 (35) 
0.49 - 15.2 32 
3b-GSS 0.01 0.73 (82.1) 
0.40 (17.9) 
0.67 67.0 81.7 48 
Complex 4a 0.15 3.12 (100) 3.12 20.8   
4a-AuNTs-CTAC 0.12 3.00 (98.7) 
1.46 (1.3) 
2.98 24.8 52.7 24 
4a-AuNSs-CTAB  0.08 2.88 (89.3) 
3.25 (10.7) 
2.92 36.5 15.2 37 
4a-GSS 0.10 3.03 (100) 3.03 30.3 78.4 51 
Complex 4b 0.02 0.88 (100) 0.88 44.0   
4b-AuNTs-CTAC <0.01 0.75 (80.9) 
0.44 (19.1) 
0.69  - 52.7 17 
4b-AuNSs-CTAB  <0.01 0.66 (81) 
0.08 (19) 
0.55 - 15.2 29 
4b-GSS 0.01 0.69 (74) 
1.23 (26) 
0.83 83.0 78.4 49 
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Complex 5 0.18      3.21 (100) 3.21 17.8   
5-AuNTs-GSH 0.06 3.09 (100) 3.09 51.5 33.2 16 
5-AuNSs-GSH 0.02 2.99 (98.5) 
0.23 (1.5) 
2.98 149.0 13.6 20 
5-AgNSs-GSH 0.16 3.10 (100) 3.10 19.4 11.1 10 
5-Ag3Au1NSs-GSH 0.13 3.17 (100) 3.17 24.4 15.1 28 
Complex 6 0.15 2.86 (100) 2.86 19.1   
6-AuNTs-GSH 0.08 2.32 (97.4) 
1.55 (2.6) 
2.30 28.8 33.2 30 
6-AuNSs-GSH 0.06 2.22 (98.9) 
4.04 (1.1) 
2.24 37.3 17.7 37 
6-AuNTs-CTAC 0.12 3.05 (100) 3.05 25.4 62.3  42 
6-AuNSs-CTAB  0.11 2.46 (100) 2.46 22.4 11.7 DLS 37 
6-AuCT 0.12 2.72 (98.3) 
0.96 (1.7) 
2.69 22.4 345 DLS 32 
6-CT 0.14 2.84 (100) 2.84 20.3 324 DLS 28 
Complex 7 0.13 3.04 (100) 3.04 23.4   
7-AuNTs-GSH 0.10 2.82 (95.4) 
2.17 (4.6) 
2.79 27.9 33.2  26 
7-AuNSs-GSH 0.06 2.51 (100) 2.51 41.8 14.9 38 
7-AuNTs-CTAC 0.11 2.82 (97.7) 
3.25 (2.3) 
2.83 25.7 62.3  33 
Complex 8 0.15 2.95 (100) 2.95 19.6   
8-AuNSs-CTAB  0.12 2.89 (95.9) 
0.94 (4.1) 
2.81 23.42 13.4 8 
8-AuNRs-CTAB 0.11 <0.01 <0.01 - 2.1 14 
 
Note: Size of the NPs of the same shape varies because they were prepared in 
different batches. aSizes are from TEM unless otherwise stated. cLoading not 
determined due to unavailability of the sample. 
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The Pc complexes showed a mono-exponential fluorescence decay as expected 
[216] while the corresponding conjugates displayed bi-exponential decays, 
and hence there are two lifetime values for the conjugates. Only the average 
lifetimes for the conjugates are presented in Table 4.1.  
The bi-exponential lifetimes observed for the conjugates, could be associated with 
the monomeric non-interacting MPc molecules, and the interaction between the 
MPc framework and the nanoparticles, resulting in unquenched and quenched 
photo-excited singlet states, respectively [217]. Different orientations of the 
phthalocyanines on the NPs could be responsible for the two lifetimes [218].  
 
Metal centres [41,42], substituents [45,46] and symmetry [32,33] of Pcs 
together with the shape and size of the linked nanoparticles [219], influence  
the fluorescence lifetime and quantum yield of complexes.  
 
i) Effect of central metal 
Complexes 3a and 3b, have a similar macrocycle and ring substituents but 
differ in the central metal, and this is the same for complexes 4a and 4b. 
Complexes 3b (ΦF = 0.03) and 4b (ΦF =0.02), containing indium as the central 
metal, displayed lower fluorescence quantum yields than their zinc 
counterparts (complex 3a (ΦF = 0.17) and 3b (ΦF = 0.15)). This shows that 
indium quenches the fluorescence lifetime and lowers the fluorescence 
quantum yield of Pcs more than zinc, Table 4.1. This is because indium is a 
heavier atom than zinc since heavy atoms are known to encourage 
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intersystem crossing to the triplet state through spin orbit coupling. A further 
decrease in the fluorescence quantum yields of complexes was observed on 
conjugation to NPs, and this was attributed to the presence of gold, another 
heavy atom in the NPs.  
The fluorescence lifetimes decreased for Pc complexes 3a, 3b, 4a and 4b in 
the presence of NPs, corresponding to a decrease in the fluorescence quantum 
yield. 
 
ii) Effect of nanoparticle shape and size 
The shape and size of the nanoparticles seems to influence the fluorescence 
behaviour of dyes. In all cases were the ΦF was significant (> 0.01), the 
conjugates to nanospheres displayed low ΦF compared to their nanotriangle 
counterparts. This may be attributed to the smaller size of the AuNSs 
compared to AuNTs, since smaller NPs have been shown to exhibit a greater 
fluorescence quenching effect [219]. Additionally, nanospheres resulted in 
more loading of complexes than nanotriangles, Table 4.1, and this could 
result in more aggregation. Aggregates are known to convert electronic 
excitation energy to vibrational energy which consequently decreases the 
fluorescence quantum yield of molecules [220].  
The behaviour is different when complexes 3a and 4a are linked to GSS. 
Though GSS has the largest size (78.4 and 81.7 nm; Table 4.1), the conjugate 
3a-GSS (ΦF = 0.13) displayed lower ΦF values than 3a-AuNTs-CTAC (52.7 nm; 
ΦF = 0.16) and this was attributed to high Pc loading in 3a-GSS as shown in 
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Table 4.1, hence aggregation in 3a-GSS. Similarly, the conjugate 4a-GSS (ΦF 
= 0.10) displayed lower ΦF values than 4a-AuNTs-CTAC (ΦF = 0.12). For 3b 
and 4b, the ΦF values were too low to be compared.  
 
iii) Effect of substituents. 
Complexes 2, 3a and 4a are symmetric and have zinc as a central metal, 
however they differ in their substituents. 3a (ΦF = 0.17) has a phenoxy 
benzothiazole group, complex 2 (ΦF = 0.19) has a phenoxy propionic acid 
group and complex 4a has a thiophine ethoxy group (Table 1.1). The low ΦF 
for complex 4a suggest that the thiophine ethoxy group quenches 
fluorescence more than the phenoxy benzothiazole and phenoxy propionic 
acid groups, even though the differences in ΦF are small.  
 
Complexes 1, 3b and 4b, are symmetrical Pcs with indium as a central metal 
in the cavity. However, these complexes have different ring substituents but 
there was insignificant difference in their ΦF values (0.02, 0.03 and 0.02 
respectively). The low ΦF values are due to the heavy atom effect of indium as 
previously explained. 
 
Complexes 7 and 8 are asymmetrical Pcs with one common ring substituent 
(a phenoxy benzothiazole group) as shown in Table 1.1. The complexes 
displayed ΦF of 0.13 and 0.15, respectively showing that the phenoxy 
propanoic acid group quenches fluorescence more than the di-O-
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isopropylidene-α-D-glucopyranose moiety, probably due to the presence of 
extra phenyl rings in complex 7 which are reported to contribute to effective 
population of the triplet state [48], hence lowering fluorescence.  
 
It is expected that ΦF and τF decrease in unison, however in some cases there 
was a significant decrease in ФF compared to τF. Following the kinetic model, 
the excited state lifetimes are directly related to the radiative lifetime (τ0) hence 
these were determined using the measured fluorescence quantum yield (ФF) 
and lifetime (τF) as shown in equation 4.1 [221,222]. 
                                    𝜏𝜏0 = 𝜏𝜏𝐹𝐹𝛷𝛷𝐹𝐹                                     (4.1) 
With this model, increase in radiative lifetime will result in a corresponding 
increase in fluorescence lifetime and a decrease in fluorescence quantum 
yield. This suggests that a decrease in fluorescence quantum yield can be 
significantly higher than the corresponding fluorescence lifetime. Indeed, all 
the complexes and the corresponding conjugates having high radiative 
lifetime showed lower fluorescence quantum yield (Table 4.1) in accordance 
with the model. 
 
iv) Effect of symmetry 
Asymmetry introduces distortions on the phthalocyanine macrocycle which 
affects their photophysical properties [32,33]. The effect of the number of 
propanoic acid groups on the fluorescence quantum yields and lifetimes was 
studied by comparing complexes 2 (with four phenoxy propanoic acid groups) 
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and 5 (with one phenoxy propanoic acid moiety). There was insignificant 
difference in the fluorescence quantum yields of the low symmetry complex 5 
(ΦF = 0.18) and the symmetrical complex 2 (ΦF =0.19) when alone.  
The effect of the number of benzothiazole phenoxy groups on the fluorescence 
quantum yields and lifetimes was studied using complexes 3a (with four 
benzothiazole phenoxy groups), 6 (with three benzothiazole phenoxy groups 
and one phenoxy propanoic acid group) and 7 (with one benzothiazole 
phenoxy group and three phenoxy propanoic acid groups). The asymmetric 
complex 6 showed a lower fluorescence quantum yield of 0.15 as well as a 
shorter lifetime of 2.86 ns compared to the quantum yield of 0.17 and lifetime 
of 3.08 ns for the symmetrical complex 3a. Similarly, the asymmetrical 
complex 7 showed a lower fluorescence quantum yield of 0.13 and a shorter 
lifetime of 3.04 ns compared to the symmetric complex 3a. This suggests that 
the asymmetric molecular structures could be potential means of enhancing 
intersystem crossing to the triplet state, hence reducing fluorescence. 
Further deactivation of the excited singlet state was observed after the 
conjugation of the complexes to metallic NPs, due to the heavy atom effect 
from Au [44]. The fluorescence lifetimes also decreased upon conjugation with 
NPs since fluorescence quantum yields and lifetimes have a direct 
relationship, except for 6-AuNTs-CTAC with increased lifetimes after 
conjugation, due to a high radiative lifetime (Table 4.1) compared to complex 
6 alone as previously explained. 
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4.2. Triplet state quantum yield (ΦT) and lifetime (τT) 
The triplet state quantum yield (ΦT) represents the fraction of molecules that 
undergoes intersystem crossing to the excited triplet state. A high triplet state 
quantum yield corresponds to low fluorescence quantum yield suggesting 
high efficiency of intersystem crossing, which is an attractive feature for MPcs 
intended for PDT as photosensitizers. A high triplet quantum yield is of great 
importance since it influences the singlet oxygen production.  
The ΦT and τT values were measured by laser flash photolysis system in argon 
saturated solutions of the complexes or their conjugates in DMSO. The triplet 
quantum yield in aqueous media could not be obtained due to the 
plausible aggregation of Pcs, since aggregation is known to deactivate the 
photoactivity of molecules [223]. Figure 4.3B, shows the triplet decay curve 
of the conjugate 3-AuNTs-CTAC in DMSO (as a representative) together with 
its transient curve (Figure 4.3A).  
The transient absorption spectrum shows a broad band between 400–600 nm 
with a maximum absorption at 500 nm, attributed to the excited triplet-triplet 
state absorption (T1→Tn). The negative peaks were also shown between 325 
and 380 nm, and between 600 and 700 nm. Considering the shape and the 
position of the negative signals, which corresponds to the absorption in the 
ground state, these can be attributed to the depletion or photobleaching of 
the phthalocyanine ground state [224].  
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Figure 4.3: (A) Transient curve and (B) Triplet absorption decay curve 
(black) and fitting (red) for 4a-AuNSs-CTAB in DMSO. 
 
 
The triplet decay curve obeyed second order kinetics, typical of MPc complexes 
at high concentration, due to triplet-triplet recombination [225]. Fitting the 
decay curve at the absorption maximum produced the triplet lifetimes and 
the obtained values together with the triplet quantum yield are summarized 
in Table 4.2. 
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Table 4.2: Triplet quantum yield and lifetime parameters of the Pcs and 
respective conjugates 
Sample ΦT (±0.01) τT (µs) (±1) ΦF (±0.01) 
Complex 1 0.65 58 0.02 
1-Ag1Au3NSs-GSH 0.79 73 < 0.01 
1-Ag3Au1NSs-GSH 0.73 58 < 0.01 
1-Ag3Au1SiNSs-APTES 0.55 81 0.01 
Complex 2 0.54 264 0.19 
2-AuNTs-GSH 0.68 244 0.13 
2-AuNSs-GSH 0.70 305 0.03 
2-AgNSs -GSH 0.67 271 0.11 
2-Ag3Au1NSs-GSH 0.69 314 0.04 
Complex 3a 0.56 149 0.17 
3a-AuNTs-CTAC  0.62 199 0.16 
3a-AuNSs-CTAB  0.68 188 0.14 
3a-GSS 0.68 132 0.13 
Complex 3b 0.75 55 0.03 
3b-AuNTs-CTAC 0.81 72 <0.01 
3b-AuNSs-CTAB  0.86 67 <0.01 
3b-GSS 0.82 48 0.01 
Complex 4a 0.47 306 0.15 
4a-AuNTs-CTAC 0.53 214 0.12 
4a-AuNSs-CTAB  0.61 202 0.08 
4a-GSS 0.64 242 0.10 
Complex 4b 0.60 225 0.02 
4b-AuNTs-CTAC 0.64 86 <0.01 
4b-AuNSs-CTAB  0.70 78 <0.01 
4b-GSS 0.72 49 0.01 
Complex 5 0.73 233 0.18      
5-AuNTs-GSH 0.80 247 0.06 
5-AuNSs-GSH 0.87 262 0.02 
5-AgNSs-GSH 0.82 274 0.16 
5-Ag3Au1NSs-GSH 0.81 290 0.13 
Complex 6 0.73 238 0.15 
6-AuNTs-GSH 0.83 229 0.08 
6-AuNSs-GSH 0.90 216 0.06 
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6-AuNTs-CTAC 0.86 180 0.12 
6-AuNSs-CTAB  0.89 227 0.11 
6-AuCT 0.81 231 0.12 
6-CT 0.74 239 0.14 
Complex 7 0.76 237 0.13 
7-AuNTs-GSH 0.85 232 0.10 
7-AuNSs-GSH 0.89 199 0.06 
7-AuNTs-CTAC 0.82 124 0.11 
Complex 8 0.51 308 0.15 
8-AuNSs-CTAB  0.62 318 0.12 
8-AuNRs-CTAB 0.71 210 0.11 
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The heavy atom effect of gold and silver was shown by the enhanced ΦT 
on linkage of Pc complexes to NPs. This applies to all cases in Table 4.2, 
where the ΦT increases for the NP-Pc conjugates. As expected high ΦT values 
were accompanied by short τT [226], and in most cases where there is 
lengthening of τT with increase in ΦT, it could be due to the protection of the 
Pc complexes by the NPs, since the NPs are much larger than the Pcs at ~1 
nm [227,228]. 
Intrinsic factors such as central metal, ring substituents and nature of 
symmetry [32,33,41,42,45,46] of Pc complexes coupled with the nature of the 
nanoparticles forming conjugates with Pcs [219], have an influence on their 
triplet lifetime and quantum yield, hence their effects will be discussed in the 
following subsections. 
 
i) Effect of central metal 
The Pc complexes displayed high triplet quantum yields (ΦT = 0.56 for 3a 
and 0.75 for 3b; ΦT = 0.47 for 4a and 0.60 for 4b), (Table 4.2) corresponding 
to their low ΦF, due to the presence of heavy atoms, Zn and In, as previously 
explained. The triplet lifetimes became shorter as the triplet quantum yields 
increased as expected [226], except for 3a-AuNTs-CTAC, 3a-AuNSs-CTAB , 
3b-AuNTs-CTAC, 3b-AuNSs-CTAB due reasons explained above.  
131 
 
ii) Effect of nanoparticle shape and size 
As shown in Table 4.2, the shape and size of the nanoparticles influences the 
triplet behaviour of conjugates. In all cases the ΦT of conjugates to AuNSs is 
greater than that of AuNTs, corresponding to lower ΦF for the former since 
the two are competing processes. 
The conjugates to GSS (4a-GSS and 4b-GSS) displayed higher ΦT values 
(Table 4.2) than AuNTs-CTAC and AuNSs-CTAB conjugates regardless of 
their large size due to the high loading capacity of GSS as explained before. 
 
iii) Effect of substituents. 
Symmetric complexes 2 (ΦT = 0.54) and 3a (ΦT = 0.56) showed higher ΦT 
values compared to 4a (ΦT = 0.47), probably due to the advantage of an extra 
phenyl rings in complexes 2 and 3a, as explained before [48]. When 
comparing 2 and 3a, the former displayed slightly lower ΦT than the latter, 
corresponding to a higher ΦF for the former.  
 
The MPcs with the benzothiazole phenoxy groups (complexes 3a and 3b), 
together with their conjugates displayed high ΦT compared to the 
corresponding thiophene ethoxy counterparts (complexes 4a and 4b) as 
shown in Table 4.2, suggesting that the former promotes intersystem 
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crossing to the triplet state more than the latter both in the presence and 
absence of NPs.   
The asymmetrical complex 7, displayed higher ΦT values than complex 8 
corresponding to its low ΦF, probably due to the presence of extra phenyl rings 
in complex 7 which are reported to contribute to effective population of the 
triplet state [48].  
 
iv) Effect of symmetry 
The low symmetry complex 5 (with one phenoxy propanoic acid group) showed 
higher triplet quantum yield than the symmetrical complex 2 (four phenoxy 
propanoic acid groups), which is in agreement with the literature that low 
symmetrical phthalocyanines possess better triplet state behaviour than their 
corresponding symmetrical analogues [32,33,229]. As stated above, the 
enhancement of the triplet quantum yield upon conjugation to NPs could be 
attributed to the promotion of intersystem crossing to the triplet state due to 
the heavy atom effect of gold and silver in the nanoparticles. 
Conjugates containing Au (a heavier atom than Ag), as expected have larger 
ΦT values compared to the Ag counterparts. The 5-Ag3Au1NSs-GSH gave a 
lower ΦT when compared to 5-AuNSs-GSH but was similar to 5-AgNSs-GSH. 
For 2-AuNSs-GSH, 2-AgNSs-GSH and 2-Ag3Au1NSs-GSH, there were only 
slight differences in ΦT values (Table 4.2). It is also possible that the Pc 
loading on the NPs affected their excited state parameters. Ag3Au1NSs 
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conjugates with the larger loading gave lower ΦT values than AgNSs 
conjugates with the lower loading (Table 4.1), probably due to aggregation in 
the former, which result in quenching of the triplet state. 
The symmetric complex 3a (with four benzothiazole phenoxy groups) 
displayed low ΦT values (Table 4.2) compared to asymmetric complexes 6 
(with three benzothiazole phenoxy groups and one phenoxy propanoic acid 
group) and 7 (with one benzothiazole phenoxy group and three phenoxy 
propanoic acid groups) as expected for asymmetric Pcs [32,33,229]. Even 
though the benzothiazole group seemed to promote intersystem crossing to 
the triplet state more than the phenoxy propanoic acid group when symmetric 
complexes 2 and 3a are compared, the opposite was observed for 
asymmetrical complexes 6 and 7. Complex 6, with more benzothiazole groups 
displayed slightly lower ΦT when compared to complex 7, with more  propanoic 
acid groups, suggesting that the propanoic acid group in an asymmetrical 
environment promotes intersystem crossing to the triplet state more than the 
benzothiazole group. The effect of the propanoic acid group was further 
displayed by the higher ΦT values of complex 7 compared to complex 5, with 
only one propanoic acid group.  
There was insignificant difference between the ΦT of complex 6 (ΦT = 0.73) 
and its chitosan (CT) conjugate (6-CT ΦT = 0.74) showing that CT has no 
effects on the photophysical properties of MPcs.  
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v) Effect of alloy NPs on complex 1, 2 and 5 
The conjugates 1-Ag3Au1NSs-GSH, 1-Ag1Au3NSs-GSH, 2-Ag3Au1NSs-GSH 
and 2-Ag3Au1NSs-GSH showed increased ΦT values in comparison to their 
respective Pc complexes alone (Table 4.2). As earlier stated, spin orbit 
coupling contribution from the heavy atoms in the NPs could be responsible 
for the marked increase in the ΦT values of the conjugates as compared to 
their respective Pc complexes alone [44]. 1-Ag1Au3NSs-GSH containing more 
Au (a heavier atom than Ag), has a larger ΦT value compared to 1-Ag3Au1NSs-
GSH with less Au. The lengthening of lifetimes for complex 1 in the presence 
of Ag1Au3NSs-GSH, and complexes 2 and 5 in the presence of Ag3Au1NSs-
GSH, may be due to the protection of the Pc complexes by the NPs. There was 
however, no change in lifetime for complex 1 in the presence of Ag3Au1NSs-
GSH. It is possible that the larger Ag1Au3NSs-GSH (18.9 nm) protected 
complex 1 more effectively than the smaller Ag3Au1NSs-GSH (15.1 nm). For 
1-Ag3Au1SiNSs–APTES, a decrease in ΦT is observed when compared to 
complex 1 alone. A decrease in ΦT values when Pcs are covalently linked to 
SiNSs has been reported before [230], and is possibly due to Pcs interlinking 
with the SiNSs, resulting in the quenching of the excited states.  The ΦT value 
for 1-Ag3Au1SiNSs–APTES, is however still reasonably high at 0.55 allowing 
for the conjugate to still be used for photosensitization. 1-Ag3Au1SiNSs–
APTES has a longer lifetime, corresponding to a decreased ΦT. 
 
135 
 
4.3. Singlet oxygen quantum yields  
A good photosensitizer should have high triplet and singlet oxygen quantum 
yields [231]. Production of singlet oxygen is dependent on the triplet state 
population and the effectiveness of energy transfer process between the 
excited triplet state of the photosensitizer and ground state molecular oxygen 
[203,232]. To determine the singlet oxygen quantum yield (Φ∆), the chemical 
photodegradation of singlet oxygen quenchers (DPBF in DMSO and ADMA in 
aqueous media) in the presence of an MPc were monitored over a period of 
time.  
 
As shown in Figure 4.4 (using complexes 7 and 3a as representatives in 
DMSO and water with 1.6% DMSO, respectively), the Q-band of the complexes 
and their conjugates remained unchanged, proving their stability over the 
irradiation period, while DPBF and ADMA degraded. In the absence of the Pc 
complexes DPBF and ADMA bands remain unchanged. The Φ∆ values are 
presented in Table 4.3. 
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Figure 4.4: Representative spectra for singlet oxygen quantum yield 
determination using a photochemical method. The spectra show the 
degradation of (A) DPBF in DMSO and (B) ADMA in water with 1.6% DMSO in 
the presence of complexes 7 and 3a respectively. 
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Table 4.3: The singlet oxygen quantum yield of the Pcs and respective 
conjugates in DMSO (and water with 1.6% DMSO in brackets). 
Pc ΦT (±0.01) ΦΔ (±0.01)  
in DMSO 
ΦΔ (±0.01)   
in water with 1.6% 
DMSO 
Complex 1 0.65 0.37  0.16 
1-Ag1Au3NSs-GSH 0.79 0.27  0.11 
1-Ag3Au1NSs-GSH 0.73 0.25  0.10 
1-Ag3Au1SiNSs- APTES 0.55 0.49  0.15 
Complex 2 0.54 0.47  0.07 
2-AuNTs-GSH 0.68 0.59  0.14 
2-AuNSs-GSH 0.70 0.58  0.15 
2-AgNSs -GSH 0.67 0.54  0.04 
2-Ag3Au1NSs-GSH 0.69 0.39  0.08 
Complex 3a 0.59 0.50  0.07 
3a-AuNTs-CTAC  0.62 0.53  0.08 
3a-AuNSs-CTAB  0.68 0.56  0.10 
3a-GSS 0.68 0.59  0.11 
Complex 3b 0.75 0.64  0.12 
3b-AuNTs-CTAC 0.81 0.69  0.13 
3b-AuNSs-CTAB  0.86 0.74  0.15 
3b-GSS 0.82 0.72  0.16 
Complex 4a 0.47 0.33  0.07 
4a-AuNTs-CTAC 0.53 0.39  0.07 
4a-AuNSs-CTAB  0.61 0.46  0.08 
4a-GSS 0.64 0.54  0.10 
Complex 4b 0.60 0.42  0.08 
4b-AuNTs-CTAC 0.64 0.52  0.09 
4b-AuNSs-CTAB  0.70 0.60  0.11 
4b-GSS 0.72 0.67  0.13 
Complex 5 0.73 0.55  0.12 
5-AuNTs-GSH 0.80 0.69  0.17 
5-AuNSs-GSH 0.87 0.72  0.23 
5-AgNSs-GSH 0.82 0.69  0.05 
5-Ag3Au1NSs-GSH 0.81 0.46  0.11 
Complex 6 0.73 0.69  0.15 
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6-AuNTs-GSH 0.83 0.75  0.20 
6-AuNSs-GSH 0.90 0.79  0.22 
6-AuNTs-CTAC 0.86 0.78  0.19 
6-AuNSs-CTAB  0.89 0.80  0.26 
6-AuCT 0.81 0.75  0.21 
6-CT 0.74 0.71  0.13 
Complex 7 0.76 0.69  0.14 
7-AuNTs-GSH 0.85 0.77  0.19 
7-AuNSs-GSH 0.89 0.79  0.21 
7-AuNTs-CTAC 0.82 0.75  0.16 
Complex 8 0.51 0.36  0.08 
8-AuNSs-CTAB  0.62  0.55  0.16 
8-AuNRs-CTAB 0.71 0.61  0.20 
 
 
 
 
 
 
 
 
 
 
 
 
 
139 
 
As shown in Table 4.3, the Φ∆ followed the same trend observed in ΦT since 
the Φ∆ value is dependent on the ΦT parameter, as previously stated except 
for the conjugates,1–Ag3Au1NSs–GSH, 1–Ag1Au3NSs–GSH, 2-Ag3Au1NSs–
GSH and 5-Ag3Au1NSs–GSH which displayed increased triplet quantum 
yields, but afforded lower singlet oxygen quantum yield than their respective 
complexes alone. The lower singlet oxygen quantum yield could probably be 
due to the screening effect caused by the capping ligand around the surface 
of the NPs, which could have prevented the interaction of the excited triplet 
state of the conjugates and the ground state molecular oxygen [232–234].  
The higher singlet oxygen quantum yield for 1–Ag3Au1SiNSs–APTES compared 
to complex 1 alone, could probably be due to the permeability of the porous 
silica matrix to ground state molecular oxygen [198,235]. Hence linking 
phthalocyanines to Ag3Au1NSs contained within a SiNSs matrix could be 
advantageous for production of singlet oxygen which is essential for 
application in areas such as PDT.  
The aqueous media is important for biological applications, hence the Φ∆ 
values were also measured in water with 1.6% DMSO since the Pc complexes 
and some conjugates are not soluble in water (1.6% DMSO was also used for 
PDT applications in Chapter 5). The Φ∆ in water (with 1.6% DMSO) were lower 
than in DMSO (Table 4.3). The low Φ∆ values in water are due to quenching 
[46] and low solubility of oxygen in water [236] . Even though the values of Φ∆ 
in water (with 1.6% DMSO) are low, the samples can still be used for PDT 
since complexes such as lutetium texaphyrin with a low singlet oxygen 
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quantum yield value of 0.11 have been employed for clinical application in 
PDT [4]. 
 
4.4. Summary of chapter  
The photophysical and photochemical properties of the complexes and their 
conjugates were studied in solution. All the studied complexes showed good 
photophysicochemical behaviour with relatively high triplet and singlet 
quantum yields. These generally increased on linkage to NPs due to the 
heavy–atom effect of gold and silver in NPs, except for the conjugates to 
complex 1, probably due to poor interaction of the excited state of the 
conjugates and molecular oxygen. 
AuNSs-CTAB conjugates yielded higher ΦT and Φ∆ values than AuNTs-CTAC 
due to the higher loading by AuNSs-CTAB probably caused by their small size 
compared to AuNTs-CTAC. However, GSS, with the largest NP size displayed 
the highest Φ∆ values compared to the AuNTs-CTAC counterparts and this 
was attributed to high loading probably encouraged by its porous nature.  
The complexes with a heavier central metal (indium) exhibited higher triplet 
and singlet quantum yields in comparison to its zinc counterparts (which is a 
relatively light metal) and this could be due to the heavy–atom effect obtained 
from the former. Asymmetrical complexes displayed relatively higher triplet 
and singlet quantum yields than symmetrical complexes, with complexes 
containing phenoxy benzothiazole and phenoxy propionic acid groups 
showing improved quantum yields than their thiophene ethoxy counterparts. 
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It is pertinent to note that improved ΦT and Φ∆ of complexes in the presence 
of the NPs could afford efficacious photosensitization which is pivotal for PDT 
in the treatment of cancer.  
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CHAPTER 5 
 
5. In-vitro dark cytotoxicity and photodynamic therapy of 
cancer 
 
This chapter discusses the in-vitro dark cytotoxicity and photodynamic 
therapy activity of phthalocyanines when alone and when conjugated to 
nanoparticles against epithelial breast cancer cell lines (MCF-7).  
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In vitro dark cytotoxicity and photodynamic therapy of the complexes and 
their conjugates were tested against MCF-7 cells using 3b (ΦΔ = 0.12), 3b-
GSS (ΦΔ = 0.16), 6 (ΦΔ = 0.15), 6-AuCT (ΦΔ = 0.21), 8 (ΦΔ = 0.08), 8-AuNRs-
CTAB (ΦΔ = 0.20) and 8-AuNSs-CTAB (ΦΔ = 0.16) as examples (and ΦΔ values 
in water containing 1.6% DMSO are shown in brackets). The dark 
cytotoxicity studies were used to evaluate the degree to which the 
photosensitizer (PS) can exert cytocidal activity at varied concentration doses 
in the absence of illumination. Cytotoxicity studies performed in the dark are 
referred to as in vitro dark cytotoxicity. In vitro dark cytotoxicity is undesirable 
for PS aimed for use in PDT applications as it results in cytocidal activity 
against both healthy and tumorigenic cells. The lower the cell viability, the 
higher the dark cytotoxicity.  
 
The stock concentration of all the complexes and their conjugates were 
prepared by dissolving each in DMSO (with an addition of 1% acetic acid for 
3-AuCT) and making the volume up with supplemented media. As a result, 
the vehicle control consisting of 1.6% DMSO (with additional 1% acetic acid 
for studies with 3-AuCT since chitosan dissolves in water with 1% acetic acid) 
in culture media (being the highest concentration of DMSO used for all 
photosensitizers used in this study) was equally tested against MCF-7 cells to 
assess the effects of the solvent against the cells. The percentage cell viability 
of the 1.6% DMSO was relatively the same as the media control alone (Figures 
5.1 and 5.2, 0 μg/mL). A fixed light dosimetry of 170 J.cm2 was used for all 
PDT studies. 
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5.1. Complex 3b and 3b-GSS  
Gradient PS concentration range of 10 μg/mL–160 μg/mL for in vitro dark 
cytotoxicity and PDT were used. 
 
5.1.1. In vitro Dark Cytotoxicity 
Complex 3b and 3b-GSS (Figure 5.1), exhibited ≥ 95% viable cells at 
concentration ≤160 µg/mL showing that the complex and its conjugate are 
relatively innocuous against the MCF-7 cells in the absence of light which is 
a good indication for an ideal PS for PDT. The absence of dark toxicity makes 
complex 3b and 3b-GSS good candidates for PDT. GSS alone (≥ 93% viable 
cells at 160 µg/mL) also showed no toxicity in the absence of light. 
 
5.1.2. Photodynamic therapy activity. 
The PDT activity of the samples was achieved under the same conditions as 
the dark cytotoxicity study but with a fixed light dosimetry of 170 J/cm2. 
When MCF-7 cancer cells were treated with the highest concentration of 
complex 3b (160µg/mL), 66% viable cells were obtained (Figure 5.1A), even 
though the Φ∆ in DMSO was high (0.64). The high percentage cell viability in 
the presence of 3b could be attributed to aggregation of the complex in 
aqueous media as shown by the low ΦΔ (0.12) values in water with 1.6% 
DMSO. However, it should be noted that the phototoxicity of the PS is 
determined by a number of factors including cell type, cellular uptake and 
localization [237]. 
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Figure 5.1: Dark toxicity and phototoxicity effects of complex 3b (A), GSS (B) 
and 3b-GSS (C) against epithelial breast cancer cells (MCF–7). Fixed 
irradiation dose = 170 J/cm2. Control = 0 μg/mL (with 1.6% DMSO in media) 
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The poor solubility and lack of cell targeting moieties in complex 3b could 
have resulted in poor uptake and localisation of the MPc hence high cell 
viability.  
Complex 3b was linked to GSS nanoparticles, hence the phototoxicity of GSS 
alone was tested against the MCF–7 cell lines. The highest concentration of 
GSS (160 µg/mL) showed cell viability of 63% (Figure 5.1B), which 
surprisingly is slightly higher than that of the MPc alone. Since GSS alone did 
not show toxicity in the dark, the phototoxicity could probably be due to the 
photothermal activity as reported before [153]. The conjugate, 3b-GSS 
afforded improved PDT activity with cell viability of 49% at 80 µg/mL and 46% 
at 160 µg/mL, Fig. 5.1C. The enhanced PDT activity for 3b–GSS compared to 
complex 3b is attributed to enhanced singlet oxygen quantum yield due to the 
presence of Au, a heavy atom as explained before, in addition to the 
phototoxicity contributions from GSS.  
 
5.2. Complex 6 and 6-AuCT.  
Gradient photosensitizer concentrations of 3.7 μg/mL to 59.2 μg/mL for 
dark cytotoxicity and PDT were used. 
5.2.1. In vitro dark Cytotoxicity  
The in vitro dark cytotoxicity data of complex 6, AuCT and 6-AuCT (Figure 
5.2), accounted for ≥ 90% viable cells at concentration ≤ 59.2 µg/mL which 
further shows that the complex and its conjugates are mostly inactive in 
the dark as expected of an ideal PS for PDT.  
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Figure 5.2: Dark toxicity and phototoxicity effects of complex 6 (A), AuCT (B) 
and 6-AuCT (C) against epithelial breast cancer cells (MCF–7). Fixed 
irradiation dose = 170 J/cm2. Control = 0 μg/mL (with 1.6% DMSO + 1% 
acetic acid in media) 
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Figure 5.3: Representative MCF-7 breast cancer cells micrographs of cells 
only (control) (A); cells in the presence of 6-Au-CT (29.6 μg/mL), without 
irradiation (B) and with irradiation (C). 
 
 
The image in Figure 5.3, shows that there was insignificant difference 
between the control cells (A) and cells treated with 29.6 μg/mL 6-AuCT (B) in 
the absence of irradiation. Both images (A and B) show that the cells reached 
confluence covering the entire surface, with some cells growing on top of one 
another. This shows absence of dark cytoxicity, making complex 6 and 6-
AuCT potential candidates for PDT.  
A
B
C
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5.2.2. Photodynamic therapy activity. 
Complex 6 showed cell viability of ≥ 54% at a concentration ≤ 59.2 µg/mL, 
Figure 5.2A. This could be attributed to the lower Φ∆ value (= 0.15) in water 
with 1.6% DMSO. Additionally, poor permeability into the cells could have 
contributed to the low PDT activity since complex 6 does not have the cell 
targeting moieties.  
The conjugate, 6-AuCT afforded improved PDT activity with a significant 
cytocidal activity of 59% (41% cell viability) at 29.6 µg/mL and 62% (38 % cell 
viabilty) at 59.2 µg/mL, Figure 5.2C. The enhanced PDT activity for 6–AuCT 
compared to complex 6 on illumination could be due to enhanced singlet 
oxygen quantum yield (Φ∆= 0.21 in water) due to the presence of Au, a heavy 
atom as explained before. Additionally, the presence of chitosan, which has 
target moieties (sugars), in the conjugate could have enhanced permeability 
to the cells since it is recognised by cell surface receptors more than complex 
6.  
AuCT alone (Figure 5.2B), displayed significant phototoxicity even though the 
cell viability was above 50% at a concentration ≤ 59.2µg/mL. The 
phototoxicity could probably be due to the photothermal activity, since gold 
is known to be a light absorber for cancer therapy [102]. It should be noted 
however that for PDT studies irradiation was done at 680 nm, and AuNPs 
absorb less at this wavelength (and most around 548 nm). Thus, the 
contribution due to photothermal activity is expected to be less than that of 
PDT. As shown in Figure 5.2B, contributions due to the presence of CT are 
minimal as shown by minimal (to no) dark toxicity for AuCT, even though it 
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is reported to induce apoptosis in cancer cells [95], while on irradiation a 
notable toxicity was probably due to the photothermal activity of gold. 
The image in Figure 5.3, shows a clear difference between the cells with 3-
AuCT (29.6 μg/mL) in the absence of irradiation (B) and after irradiation (C) 
showing that there is less survival of cells when the conjugate is exposed to 
light.  
 
 
5.3. Complex 8, 8-AuNRs-CTAB and 8-AuNSs-CTAB.  
In vitro dark cytotoxicity and photodynamic therapy of complex 8 and its 
conjugates with both AuNRs-CTAB and AuNSs-CTAB were tested against 
MCF-7 cells. Gradient photosensitizer concentration range of 10 μg/mL to 
160 μg/mL for in vitro dark cytotoxicity and PDT were used. Figure 5.4, 
shows the dark toxicity and phototoxicity histograms of complex 8, 8-AuNRs-
CTAB and 8-AuNSs-CTAB. Histograms for AuNRs-CTAB and AuNSs-CTAB 
alone are shown in Figure 5.5. 
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Figure 5.4: Dark toxicity and phototoxicity effects of complex 8 (A), 8-AuNRs-
CTAB (B) and 8-AuNSs-CTAB (C) against epithelial breast cancer cells (MCF–
7). Fixed irradiation dose = 170 J/cm2. Control = 0 μg/mL (with 1.6% DMSO 
in media) 
0
20
40
60
80
100
120
0 10 20 40 80 160
Ce
ll 
Vi
ab
ili
ty
 (%
)
Concerntration (µg/mL)
Dark toxicity PhototoxicityA
0
20
40
60
80
100
120
0 10 20 40 80 160
Ce
ll 
Vi
ab
ili
ty
 (%
)
Dark Toxicity PhototoxicityB
0
20
40
60
80
100
120
0 10 20 40 80 160
Ce
ll 
Vi
ab
ili
ty
 (%
)
Concerntration (µg/mL)
Dark Toxicity Phototoxicity
C
152 
 
 
 
Figure 5.5: Dark toxicity and phototoxicity effects of AuNRs-CTAB (A) and 
AuNSs-CTAB (B) against epithelial breast cancer cells (MCF–7). Fixed 
irradiation dose = 170 J/cm2.  
 
 
5.3.1. In vitro Dark Cytotoxicity 
As shown in Figure 5.4A, complex 8 and its conjugate to AuNSs-CTAB (8-
AuNSs-CTAB) Figure 5.4C, accounted for ≥ 90% viable cells at concentration 
≤ 160 µg/mL which further lay credence to the innocuous behaviour of 
phthalocyanines when in dark without light activation. 8-AuNRs-CTAB on the 
other hand accounted for ≥ 85% viable cells at concentration ≤ 160 µg/mL. 
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viable cells at concentration ≤ 160 µg/mL. The slight toxicity was attributed 
to the CTAB adsorbed on the surfaces of the nanorods.  
The toxicity of the CTAB-capped nanorods has been reported before [238–243] 
and has been attributed to residual CTAB on the surfaces of the rods and not 
the rods themselves. It is noteworthy that the presence of Pcs in the conjugate 
decrease the dark cytotoxicity observed in the CTAB-capped nanorods alone, 
Figure 5.4B. This suggests that most of the CTAB on the nanorods were 
replaced by the Pc on conjugation 
 
5.3.2. Photodynamic therapy activity. 
As earlier stated, a fixed light dosimetry of 170 J/cm2 and gradient 
photosensitizer concentration range of 10 µg/mL to 160 µg/mL were used 
against the MCF–7 cells. Complex 8 alone  (Figure 5.4A) showed cell viability 
of > 50% at concentrations ≤ 160 µg/mL. This could be attributed to 
aggregation in aqueous media, which leads to lower singlet oxygen generation 
(Φ∆ = 0.08). The nanoparticles alone (Figure 5.5) displayed phototoxicity 
probably due to the photothermal activity of gold, known to be a light absorber 
for cancer therapy [244,245]. The conjugate, 8-AuNRs-CTAB (Figure 5.4B) 
afforded superior PDT activity with less than 50% viable cells at 
concentrations ≥ 40µg/mL in comparison with 8-AuNSs-CTAB (Figure 5.4C) 
with less than 50% viable cells at a higher concentration of 80µg/mL. This is 
also shown in Figure 5.6B, when the two are compared at the same 
concentration. The superior PDT activity of 8-AuNRs-CTAB (Φ∆= 0.20 in water 
with 1.6% DMSO) compared to 8-AuNSs-CTAB (Φ∆= 0.16 in water with 1.6% 
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DMSO) is attributed to the higher singlet oxygen quantum yield in water (with 
1.6% DMSO; Table 4.3), in addition to the phototoxicity of nanorods. It should 
be noted that for the PDT studies, excitation was performed at 680 nm and 
AuNRs-CTAB (with SPR bands at 519nm and 662 nm) absorb more light at 
this wavelength than AuNSs-CTAB (with SPR bands at 525 nm). The 
enhanced PDT activity for the conjugates compared to complex 8 alone is 
attributed to the phototoxicity of NPs in addition to the enhanced singlet 
oxygen quantum yield of the conjugates as shown in Table 4.3, due to the 
presence of Au, a heavy atom and light absorber, as explained before. 
 
 
5.4. Comparison of the in vitro dark cytotoxicity and PDT activity of 3b-
GSS, 8-AuNRs-CTAB, 8-AuNSs-CTAB at 160 μg/mL and 59.2 μg/mL for 
6-AuCT 
In vitro dark cytotoxicity and photodynamic therapy of the conjugates 3b-GSS, 
8-AuNRs-CTAB, 8-AuNSs-CTAB at 160 μg/mL and 6-AuCT at 59.2 μg/mL 
(which is their highest concerntration used) against MCF-7 cells were 
compared. Figure 5.6A, shows the dark toxicity histograms and Figure 5.6B 
phototoxicity histograms.  
 
5.4.1. In vitro Dark Cytotoxicity 
As shown in Figure 5.5A, 3b-GSS showed the highest cell viability at ≥ 
95% at concentration ≤ 160 µg/mL while 6-AuCT and 8-AuNRs-CTAB 
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showed ≥ 90% at concentration ≤ 59.2 µg/mL for 6-AuCT and ≤ 160 µg/mL 
for 8-AuNRs-CTAB. 8-AuNRs-CTAB on the other hand accounted for ≥ 85% 
viable cells at concentration ≤ 160 µg/mL attributed to the toxicity of CTAB 
as previously stated. The levels of CTAB in 8-AuNRs-CTAB and 8-AuNSs-
CTAB are different probably due to the differences in the purification stage 
of the conjugates (suggesting more residual CTAB in the former than the 
latter).  
 
 
Figure 5.6: A) Dark toxicity and B) phototoxicity effects of 3b-GSS, 8-AuNRs-
CTAB, 8-AuNSs-CTAB at 160 μg/mL and 6-AuCT at 59.2 μg/mL against 
epithelial breast cancer cells (MCF–7). Fixed irradiation dose = 170 J/cm2.  
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5.4.2. Photodynamic therapy activity 
As shown in Figure 5.5B, 8-AuNRs-CTAB showed ≥ 36% cell viability at 
concentration 160 µg/mL, while 6-AuCT with a lower concentration of 59.2 
µg/mL showed ≥ 38% cell viability. 8-AuNSs-CTAB and 3b-GSS showed the 
lowest PDT activity of the studied conjugates with ≥ 46% viable cells at 160 
µg/mL. 6-AuCT (59.2 µg/mL) showed the best PDT activity of the studied 
conjugates since it showed ≥ 38 % viable cells at less than half the 
concentration of 8-AuNRs-CTAB (160 µg/mL).  
The conjugate 3b-GSS, has higher cell viability on illumination due to the low 
Φ∆ and probably poor cellular uptake.The conjugates to complexes 6 and 8, 
have an advantage of asymmetry but 6-AuCT has sugar moieties from 
chitosan which improves its solubility and cellular uptake hence the superior 
PDT activity than complex 8, with protected sugars. The protecting 
isopropylidene groups in complex 8, reduce solubilty in aqueous media and 
the cellular uptake.  
 
 
5.5. Summary of chapter  
In vitro dark cytotoxicity and photodynamic therapy of complexes 3b, 3b-GSS, 
complex 6, 6-AuCT, complex 8, 8-AuNRs-CTAB and 8-AuNSs-CTAB against 
MCF-7 cells were presented.  The complexes were relatively not toxic in the 
dark, with complex 3b, and 3b-GSS, showing ≥ 95% viable cells at 
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concentration ≤160 µg/mL; complex 8 and 8-AuNSs-CTAB having ≥ 90% 
viable cells at concentration ≤ 160 µg/mL. However, 8-AuNRs-CTAB showed 
slight toxicity attributed to residual CTAB on the surface of nanorods. 
Different concentrations were used for complex 6, AuCT and 6-AuCT, 
which showed ≥ 90% viable cells at concentrations ≤ 59.2 µg/mL. The 
minimum dark toxicity displayed by complexes 3b, 3b-GSS, complex 6, 6-
AuCT, complex 8 and 8-AuNSs-CTAB, make them good candidates for real 
life PDT applications. 
All complexes when alone, displayed poor phototoxicity with > 50% cell 
viability at concentrations ≤ 160 µg/mL. This could be attributed to 
aggregation in aqueous media, which leads to lower singlet oxygen generation. 
However, on linkage to NPs there was reduced cell viability, with 3b-GSS 
showing 46% viable cells at 160 µg/mL; 6-AuCT 38% viable cells at 59.2 
µg/mL; 8-AuNRs-CTAB and 8-AuNSs-CTAB showing 39% and 46% viable 
cells respectively at 160 µg/mL.  
The conjugate 6-AuCT showed both minimum dark toxicity and the best 
PDT activity of all complexes and conjugates studied, making it a 
potential candidate for real life PDT applications. 
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CHAPTER 6 
 
6. Conclusions and recommendations 
 
This chapter summarizes the results obtained for the studies conducted and 
reported in this thesis and recommendations. 
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6.1. Conclusion  
 This work presents the successful synthesis and characterization of new 
symmetric and asymmetric Pcs functionalized at the peripheral position. The 
Pcs were characterised using FTIR, UV-Vis, 1HNMR, MALDI-TOF mass 
spectroscopies and elemental analyses. The prepared Pcs were soluble in 
DMSO and exhibited monomeric behaviour in solution. These were further 
linked to various gold containing NPs through either Au-S/Au-N self-
assembly or amide bond formation from functionalised NPs. FT–IR 
spectroscopy was used to confirm the successful formation of the amide bond 
and X–ray photoelectron spectroscopy was used to confirm the Au-S/Au-N 
bonds.  
The effect of metal centres, substituents and symmetry of Pcs together with 
the shape and size of the linked nanoparticles on the photochemical and 
photophysical behaviour of Pcs was studied. Heavy atoms as metal centres, 
substituents with extra phenyl rings and asymmetry of Pcs were shown to 
promote intersystem crossing resulting in high triplet and singlet oxygen 
quantum yields.  
The presence of gold/silver containing nanoparticles enhanced the triplet and 
singlet oxygen quantum yields of Pcs and this was attributed to the heavy 
atom effect of the nanoparticles.  However, 1–Ag3Au1NSs–GSH, 1–Ag1Au3NSs–
GSH, 2-Ag3Au1NSs–GSH and 5-Ag3Au1NSs–GSH displayed increased triplet 
quantum yields, but afforded lower singlet oxygen quantum yield than their 
respective complexes alone, probably signifying poor interaction of the excited 
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triplet state of the conjugates and the ground state molecular oxygen, and 
this was  attributed to the screening effect caused by the capping ligand 
around the surface of the NPs.  
The nanoparticle shape and size were also shown to influence the 
photochemical and photophysical behaviour of Pcs studied. AuNSs-CTAB 
afforded high triplet and singlet oxygen quantum yields than AuNTs-CTAC 
due to the small size of the former, that loaded more Pcs due to a higher 
surface area than AuNTs-CTAC. However larger GSS nanoparticles also 
afforded higher triplet and singlet oxygen quantum yields than AuNSs-CTAB 
due to high loading which was attributed to the porous nature of SiNSs in 
GSS that increases the surface area for loading. 
Furthermore, in vitro dark cytotoxicity and photodynamic therapy of 
complexes 3b, 3b-GSS, complex 6, 6-AuCT, complex 8, 8-AuNRs-CTAB and 
8-AuNSs-CTAB against MCF-7 cells was tested. All complexes and conjugates 
showed minimum dark toxicity making them applicable for PDT except 8-
AuNR-CTAB which showed slight dark toxicity probably due to the presence 
of residual CTAB on the surfaces of NPs. All complexes displayed poor 
phototoxicity with > 50% cell viability at concentrations ≤ 160 µg/mL, 
however the conjugates showed < 50% cell viability at concentrations ≤ 160 
µg/mL probably to the heavy atom effect of gold in the NPs, in addition to 
reduced aggregation. The conjugates 3b-GSS, 6-AuCT and 8-AuNSs-CTAB 
showed both minimum dark toxicity and better PDT activity than Pc 
complexes alone making them good candidates for real life PDT 
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applications, however 6-AuCT was the best conjugate since displayed 
the best PDT activity of all complexes and conjugates studied. 
 
6.2. Recommendations 
The synthesised Pcs were not soluble in aqueous media, hence the cell 
viability of > 50% in PDT studies. Efforts will be made to synthesize water 
soluble Pcs and possible conjugation to gold containing NPs. PDT activity  
of the Pcs will be tested using different cancer cells. 
Water soluble asymmetric Pcs, with indium as a central metal will be 
synthesised for improved singlet oxygen quantum yield and better cellular 
uptake.  
More glycosylated asymmetric Pcs will be synthesised, and efforts made to 
unprotect the sugars for improved water solubility and cellular uptake.  
For the effect of NPs size, attempts will be made to separate the NPs especially 
nanotriangles into different sizes and possible evaluate the effect of different 
sizes of nanotriangles on the photophysical and photochemical properties of 
Pcs. 
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